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Introduction  
 
Activins are dimeric polypeptide growth factors which belong to the transforming growth factor-β 
(TGF−β) superfamily. This extended family comprises a large number of structurally related 
polypeptide growth factors that regulate many fundamental cellular processes, such as cell 
proliferation, lineage determination, differentiation and apoptosis (1, 2). In the TGF−β superfamily, 
activins are unique and multifunctional factors that can stimulate hormone production in ovarian 
and placental cells, support neuronal cell survival, influence cell-cycle progress positively or 
negatively depending on cell type, and induce mesodermal differentiation at least in amphibian 
embryos (3-6). Moreover, erythroid differentiation factor, isolated from the conditioned medium of 
stimulated human monocytic cell line, has been found to be identical to activin A (7). In several 
tissues, activin signalling is antagonized by its related heterodimer, inhibin. The nomenclature of 
inhibins and activins reflects their discovery as functional antagonists in the release of follicle-
stimulating hormone (FSH) from the pituitary: inhibin prevents whereas activin promotes FSH 
secretion and synthesis (8). In addition, other proteins may regulate activin bioactivity as well. The 
activin binding-protein, follistatin (FS), is well characterized and the effects of activin can be 
counteracted by follistatin in all systems tested (4). 
 
Learning the molecular basis of activin receptors provides a better understanding of the 
multifunctional nature of activins. To date extensive evidence obtained suggests a general signal 
transduction mechanism for TGF−β and related ligands. Two distinct transmembrane 
serine/threonine kinases known as type I and type II receptors are needed for signal transduction. 
Ligand induced association of type I and II receptors results in the phosphorylation and consequent 
activation of the type I receptor, which is required for downstream signal cascades. Smad proteins 
activated by type I receptors carry signal to the nucleus, and together with other proteins direct 
transcriptional responses (9-13). 
 
At the beginning of the 1990s, when this study began, relatively little was known about the 
expression and regulation of activin β-subunits in human tissues. There was some experimental 
evidence that activins are involved in regulation of embryogenesis (14, 15) but there was no 
information concerning the expression of activin subunits or its receptors in developing human 
embryo. At that time only the mouse type II activin receptor had been discovered in vertebrates 
although high affinity binding sites for activin were detected in several different cell culture 
models, such as human erythroleukemia K562 cells (16, 17) and ovarian granulosa cells (18). The 
aim of this thesis was to clone human type II activin receptor cDNAs. Additionally, we wanted to 
study how activin β-subunits and activin receptor transcripts are regulated in activin responsive cell 
culture models. 
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Review of the literature 
1. Structure and function of activin and activin binding proteins 
1.1 Isolation of activins 
 
Inhibin was isolated in 1985 from porcine ovarian follicular fluid, by four independent research 
groups, as a protein, which displayed potent activity to suppress follicle-stimulating hormone 
(FSH) secretion in cultured rat anterior pituitary cells (19-22). It was found to be a glycoprotein 
hormone of 32 kD consisting of two subunits, a common 18 kD α-subunit and either a 14.7 kD βA- 
or a 14 kD βB-subunit, yielding inhibin A or inhibin B, respectively. In side fractions during 
purification of inhibin 25 kD proteins that could promote FSH secretion in vitro were also isolated 
(23, 24). Surprisingly, these proteins turned out to be homo- or heterodimers of the βA- or βB-
subunits linked together by disulphide bonds. The proteins were subsequently named as activin A 
(βAβA), activin B (βBβB) and activin AB (βAβB) (Fig. 1). Molecular cloning of βA- and βB-subunits 
from an human ovarian cDNA library revealed that the β-subunits were 70% homologous to each 
other, and the position of seven cysteine residues in the carboxy-terminus were perfectly conserved 
indicating structural similarity to other members of TGF-β superfamily (25, 26). 
 
 
β-subunit precursors
pro-βA (50-54 kDa)
βA (14 kDa)
pro-βB (50-54 kDa)
βB (14 kDa)
mature activins
activin A
(βAβA)
activin AB
(βAβB)
activin B
(βBβB)
25 kDA
prepro-α (57 kDa)
αNαC (44kDa)
α (18 kDa)
α-subunit precursors
mature inhibins
= signal peptide = pro-region = disulphide bond = glycosylation site
32 kDa
inhibin A
(αβA)
inhibin B
(αβB)
 
 
 
 
Figure 1. Structure of activin and inhibin polypeptide chains. The α- and β-subunits are 
produced as larger precursor proteins, prepro-α, pro-βA and pro-βB, that include a signal peptide 
and pro-region, both of which are cleaved to form the mature α- or β-subunit. Activins are dimers 
consisting of two β-subunits joined by disulphide bridges. Inhibins are heterodimers of α- and 
either βA- or βB-subunits. Size in kilodaltons (kDa) is indicated to the right of each subunit. 
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1.2 Activin subunits and their regulation 
1.2.1. Human βA-subunit 
 
The human βA-subunit mRNA encodes a 426 aa pre-proprotein containing an N-terminal 28 aa 
signal peptide followed by a pro-region (25). The C-terminal mature 116 aa polypeptide is 
proteolytically cleaved from the pre-pro-region at an arginine rich processing site (RXXR) to form 
the dimeric, bioactive protein (25, 27, 28). The proregion of βA-subunit is involved in the correct 
folding, dimerization and secretion of the activin protein (29). In addition, all of the nine conserved 
cysteine residues in the mature part of the activin βA-subunit are essential for either the biosynthesis 
or biological activity of activin A (30). Human (25), porcine (31), bovine (32), rat (33, 34) and 
mouse (35, 36) βA-subunits are highly conserved and the mature parts of the proteins are identical 
between these species. 
 
The human activin βA-subunit gene is assigned to chromosome 7 locus 7p15-p14 (37). It consists of 
three exons, the first of which contains only 5' noncoding sequences (26, 38, 39). The human βA-
gene is transcribed to several distinct mRNAs in the size range of 1.7- to 6.4-kb (7, 40-43), 
probably reflecting the use of alternative polyadenylation signals (44) or different transcription start 
sites (45). The 5' noncoding region has been characterized in detail, leading to the identification of 
conserved promoter sequences with several potential enhancer sites. Of those sites, at least the 12-
0-tetradecanoyl phorbol 13-acetate (TPA) responsive element (TRE) and cyclic AMP responsive 
element (CRE) binding sites are functionally active and are involved in regulation of βA-subunit 
gene expression in human fibrosarcoma HT1080 cells (39). Recently, the structure of rat activin 
βA-subunit gene has been analysed, showing strong conservation of the potential transcription 
factor binding sites (46). In human bone marrow cells two essential regions for the promoter 
activity have been found, one between 0.2- and 0.25-kb and the other 2.5- and 3.6-kb upstream of 
the start codon (45). The distal promoter region contains TATA-box whereas the other region does 
not contain TATA or CAAT boxes, but instead has several potential Sp1- binding sites. 
1.2.2. Human βB-subunit 
 
The βB-subunit is synthesized as a 407 aa precursor protein containing a hydrophobic signal 
sequence and a proregion of 292 aa separated from the mature 115 aa C-terminal by basic amino 
acids (aa) (47). Like the mature part of the βA-subunit, the activin βB-subunit also lacks putative 
glycosylation sites. The β-subunits share similar a cysteine distribution and their mature regions 
show about 70% aa sequence homology with each other (31). 
 
The human βB-subunit gene is located on chromosome 2qcen-q13 (37) and consists of two exons 
separated by a 2.5 kb intron (47). According to the DNA sequence analysis, no TATA or CAAT-
like elements have been identified. However, the promoter region is extremely GC-rich with 
multiple potential Sp1- binding sites and three CRE sequences (47). Two βB-subunit mRNAs of 
3.8- and 4.8-kb in length have been observed in human tissues (48). In rat granulosa cells βB-
subunit transcripts originate from two independent transcriptional start sites of the gene, and they 
are also differentially regulated (49). 
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1.2.3. Other β-subunits 
 
The properties of the more recently described activin subunits βC (50), βD (51) and βE (52), are 
largely unknown. Human activin βC- and βE- subunits have been cloned from a human liver cDNA 
library. They consist of 352 aa and 350 aa from which a mature C-terminal fragment is 116 aa and 
114 aa, respectively. Both subunits show about 50% aa identity to mature βA- and βB-subunits (50, 
52). Activin βC- and βE-subunit genes are organized similarly, consisting of two exons (53). It has 
been suggested that the βC- and βE-subunit genes have been generated by tandem duplication of an 
ancestral gene because they are closely linked to each other. They also share a similar liver specific 
gene expression pattern in adult mouse. Activin βD-subunit has been cloned from Xenopus laevis 
and it shows highest homology to human βC-subunit (60%) although the putative mature part of the 
protein is slightly shorter (114 aa) (51). The mRNA microinjection studies have shown that βD-
subunit is able to stimulate mesoderm induction in early development of Xenopus laevis in a similar 
manner to activin A (51). Although the functions of βC- and βE- subunits are not yet known, recent 
studies demonstrate that all possible homo- and heterodimers can be formed by recombinant co-
expression of the βA-, βC- and βE-subunit cDNAs (54-56). 
1.2.4. Transgenic mice models of activin β-subunits 
 
Gene targeting by homologous recombination has been used to address the physiological roles of 
the activin subunits (Table 1). Activin βA-subunit deficient mutant mice, ActβA-/-, develop normally 
throughout fetal life but die within 24 h of birth from craniofacial abnormalities that prevent 
suckling. These defects include cleft palate, absence of whiskers and lack of lower incisors (57). 
These findings suggest that the activin βA-subunit is essential only in the development of a few 
tissues. 
 
Mice homozygous for a deletion of the βB-subunit gene, ActβB-/-, are viable and fertile but suffer 
eyelid defects. Moreover, female mice fail to nurse their newborns properly (58, 59). This 
phenotype suggests that the proteins activin B, activin AB and inhibin B are not essential for 
murine embryonic development and that the presence of the βA-subunit may possibly replace the 
missing βB-subunit. Mice deficient in both activin βA- and βB-subunits, ActβA-/- x ActβB-/- display 
the defects of both activin βA and βB mutant mice but no additional defects are seen (57). 
 
Recently, it has been shown that the sequence encoding the mature part of the βB-subunit can 
function as a hypomorphic allele of the βA-subunit, rescuing in part the phenotype of the activin βA-
subunit deficient mice in early development (60). However, the biological effects of activin βA in 
testis and ovary development cannot be fully substituted by activin βB. Mutant mice deficient in 
both liver-specific activins, ActβC-/- x ActβE-/-, are viable and fertile suggesting that activin βC- and 
βE –subunits are not essential for liver growth, differentiation or regeneration (61). Normal 
mesoderm formation in activin β-subunit deficient mice shows that activins are not required for 
mesoderm induction in mammals although activins have been identified as a potent mesoderm 
inducing factor in Xenopus. The lack of such defects in null mice may be due to functional 
compensation of other activin subunits or TGF-β superfamily members. 
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Table 1. Targeted inactivation of activin subunits 
 
Transgenic mouse model Phenotype        References 
Activin βA-/- postnatal lethality       (57, 62) 
 craniofacial anomalies;  
cleft palate,  
lack of whiskers and incisors and lower molars 
 
Activin βB-/-    viable         (58, 59) 
nursing defects 
reproductive abnormalities in females 
      defects in eyelid closure at birth 
 
Activin βC-/-    viable; no obvious abnormalities    (61) 
 
Activin βE-/-    viable; no obvious abnormalities    (61) 
 
Activin βA-/- x βB-/-   postnatal lethality       (57) 
eyelid closure defects at birth 
      craniofacial anomalies 
 
Activin βC-/- x βE-/-   viable; no obvious abnormalities    (61) 
 
1.3 TGF-β superfamily 
 
The TGF−β superfamily is a large family of structurally related growth and differentiation factors 
named according to the first family member identified [for review see, Massagué et al., Kingsley et 
al. and Hu et al. (63-65)]. TGF−β was originally identified based on its ability to induce anchorage-
independent growth of normal rat kidney fibroblasts (66). Subsequently it was found to be involved 
in a wide variety of cellular functions, which can be either growth promoting or growth inhibiting 
depending on cell type. For example, it controls the production and remodelling of the extracellular 
matrix, modulates immune and inflammatory responses and regulates angiogenesis, embryogenesis 
and gonadal differentiation. There are three highly related mammalian TGF−β isoforms (TGF-β1, -
β2 and -β3), chicken TGF-β4 and frog TGF-β5. Like activins, various members of the 
TGF−β superfamily are initially synthesized as larger precursor molecules, which are cleaved to 
release mature the C-terminal protein. Pro-domains are usually poorly conserved between different 
family members and the mature region contains most of the sequence similarities by which new 
family members are usually recognized. 
 
The TGF−β superfamily includes over 40 members divided into several subgroups according to 
their structural and biological similarities (10) (Fig. 2). In addition to TGF−β and activin 
subfamilies, the bone morphogenic proteins (BMPs) form a large and heterogenous subgroup of 
TGF−β family members. Some family members, such as inhibin α, growth differentiation factor 9 
and anti-Müllerian hormone, are only distantly related to other members of the TGF−β superfamily 
and do not belong to any particular subgroup. 
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Although the mature regions of activin A and TGF−β share nine conserved cysteines, most of the 
members of the TGF−β superfamily contain only seven of these nine cysteine residues. 
Crystallography studies on TGF-β2 and OP-1/BMP-7 have shown that in biologically active 
proteins six of these cysteines are closely grouped to form a rigid structure called a cystine knot 
(67-69). The knot is formed by intrachain disulphide bonds and probably accounts for the strong 
resistance of many TGF−β family members to heat, denaturants and extremes of pH. The 
remaining cysteine residue in each monomer forms an additional disulphide bond that links two 
monomers into a dimer. It has been predicted that due to the conservation of cysteines, other 
TGF−β related molecules contain a similar general folding pattern. 
BMP-4
BMP-2
Dpp
BMP-10
BMP-9
GDF-5
BMP-5
BMP-6
BMP-7
BMP-8
60A
Scw
GDF-1
inhibin α
BMP-3
GDF-10
activin βA
activin βC
activin βB
activin βD
activin βE
activin d
dorsalin
Vg-1
GDF-3
nodal
Dbl-1
GDF-9
GDF-9B
GDNF
Daf-7
TGF-β1
TGF-β2
TGF-β3
TGF-β4
TGF-β5
AMH
GDF-15
GDF-11
GDF-8
myoglianin
Figure 2. Dendrogram of the TGF−β superfamily ligands. The alignment tree indicates the relative 
level of amino acid sequence identity between TGF-β superfamily members. The amino acid sequences used are 
mature parts of TGF-β superfamily ligands from human, unless otherwise indicated. The sequences have been 
compared using the ClustalW program. The Genbank accession numbers for ligands are as follows: inhibin α (P05111), 
activin βA (P08476), activin βB (A40150), activin βC (JC2347), X. laevis activin βD (D49543), activin βE (P58166), D. 
melanogaster Activin β (AF054822), TGF-β1 (224622), TGF-β2 (557563), TGF-β3 (AAA61161), TGF-β4 (O00292), 
TGF-β5 (AAB64441), BMP-2 (P12643), BMP-3 (P12645), BMP-4 (BMHU4), BMP-5 (P22003), BMP-6 (P22004), 
BMP-7 (P18075), BMP-8 (P34820), BMP-9 (AAD56960), BMP-10 (AAC77462), GDF-1 (NP001483), M. musculus 
GDF-3 (NP032134), GDF-5 (JC2347), Myostatin/GDF-8 (AAB86694), GDF-9 (NP005251), GDF-9B (O95972), 
GDF-10 (NP004953), GDF-11 (NP005802), GDF-15 (NP004855), AMH (P03971), GDNF (P39905), G. gallus 
dorsalin (AAA48752), D. melanogaster 60A (A43918), D. melanogaster Scw (AAA56872), D. melanogaster 
myoglianin (AF132814), D. melanogaster Dpp (P07713),  X.laevis Vg-1 (P09534), M. musculus nodal (S29718), C. 
elegans DBL-1 (AF004395) and C. elegans Daf-7 (U72883). 
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1.4. Follistatin and other activin binding proteins 
 
Activins interact with various binding-proteins, of which follistatin has been most extensively 
studied. Follistatin was originally purified from follicular fluid as a monomeric glycoprotein that 
could inhibit FSH secretion from cultured rat pituitary cells (70, 71). Follistatin exists as three 
different isoforms produced from a single gene either by alternative mRNA splicing (72) or by 
proteolytic modification of the core protein (73). Structurally it is composed of a signal peptide, 
followed by the N-terminal domain and three follistatin domains (72). Follistatin neutralizes the 
biological effects of activin in a number of biological systems by preventing activin to bind its type 
II receptors (74, 75). It has been shown that a single follistatin has one activin binding site, which 
can bind either activin βA- or βB-subunits (76-78) whereas activins have two binding sites for 
follistatin (76). Follistatin binds to activin A with high affinity and under physiological conditions 
the interaction can be considered to be virtually irreversible (79, 80). Follistatin-activin complexes 
bound to plasma membrane proteoglycans are internalised and then degraded through the 
lysosomal pathway (81). Follistatin does not affect the bioactivity of inhibins, despite its capability 
to bind to the β-subunit present in inhibin (76). 
 
Follistatin-related protein (FSRP) is a recently described new activin binding protein (82, 83). 
FSRP and follistatin share many structural features like a primary sequence homology, a common 
exon/intron arrangement and domain structure. However, the affinity of FSRP for activin A is 
lower than that of FS and they differentially neutralize exogenous vs. endogenous activin, 
suggesting nonoverlapping cellular functions (84). A serum protein, α2-macroglobulin, has been 
implicated as a low-affinity binding protein of activin A (85). It as been suggested that α2-
macroglobulin may play a role as a carrier for activin in the circulation (86). The extracellular 
protein Cerberus has been shown to block signalling by activin in a Xenopus animal cap model 
(87). 
 
Another group of activin binding proteins are accessory proteins and pseudoreceptors. Endoglin is a 
cell surface molecule, which can interact with several TGF−β family members. As an accessory 
protein it binds to multiple receptor complexes, such as those containing ActR-II or ActR-IIB, 
modulating the activity of the receptor kinase complexes (88). The pseudoreceptor, named BMP 
and activin membrane- bound inhibitor (BAMBI), has a type I receptor-like structure but lacks a 
full intracellular domain (89). It competes with ActR-Is for association with ActR-II, and hence 
inhibits signal transduction by activin (Fig. 5). 
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2. Activin-mediated signalling 
 
TGF−β superfamily members exert their diverse biological effects through a receptor complex 
formed by two distantly related types of transmembrane serine/threonine (ser/thr) kinase proteins 
that fall into two classes, type I receptors and type II receptors (13, 90). Vertebrate type I receptors 
can be divided into two different groups according to their sequence homology at the kinase 
domain and their signalling activities (Table 2). One group includes type I TGF-β receptor (TβR-I), 
type IB activin receptor (ActR-IB) and activin-like receptor-7 (ALK-7), and the other one includes 
type I and IB BMP receptors (BMPR-I and BMPR-IB), type I activin receptor (ActR-I) and activin-
like receptor 1 (ALK-1). 
 
 
Table 2. Mammalian type I and II receptor families. 
 
Type I receptors  References     Type II receptors References  
ALK-1    (91, 92) (93)     ActR-IIA  (94) 
ActR-I (ALK-2)  (91, 92, 95-98)    ActR-IIB  (99) 
BMPR-I (ALK-3)  (92)       TβR-II   (100) 
ActR-IB (ALK-4)  (13, 91, 92, 101)     BMPR-II (102-105) 
TβR-I (ALK-5)  (91, 106)      AMHR-II  (107) 
BMPR-IB (ALK-6)     (108) 
ALK-7        (109, 110) 
 
 
 
In activin and TGF−β signaling, ligand induced activation of the type I and type II receptors allows 
the type II receptor to phosphorylate serine and threonine residues in the GS-domain (= gly and ser-
rich domain) of the type I receptor, thus, inducing its kinase activity (Fig. 3) (11, 13, 111, 112). 
Type I receptors for activin and TGF−β can only recognize ligand that is bound to the type II 
receptor (95, 96, 106, 113). Type II receptors can bind ligand independently of the type I receptor, 
but they are unable to signal without the type I receptor (90, 95, 114, 115). This phenomenon was 
originally revealed by analyzing the receptor phenotype in TGF−β resistant cell mutants (116). 
Ligand binding does not increase the overall phosphorylation of type II activin receptors or their 
kinase activity in vitro (90), suggesting that type II receptors are constitutively active kinases that 
require the ligand to interact with type I receptor that is considered as a substrate. Once 
phosphorylated, the type I receptor activates the downstream target. Thus it appears that the 
specificity in signalling is mainly determined by the type I receptor. Co-operative binding mode is 
typical for BMP subfamily receptors. BMPs bind weakly to the type I receptor in the absence of 
type II receptor, but the presence of type II receptors accelerates the ligand binding to type I 
receptors (Fig. 3) (13, 117, 118). 
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Figure 3. Two modes of ligand binding in TGF−β receptor family members. In sequential 
binding, ligand binding to the type II receptor kinase (1) is followed by formation of a complex 
with the type I receptor (2), whereas the co-operative mode requires both type I and type II 
receptors for high affinity ligand binding. In the heterotetrameric receptor complex (3), the 
constitutively active, dimeric type II receptor kinase complex phosphorylates the GS-domain of the 
dimeric type I receptor complex (4) inducing activation of type I receptor kinases and transduction 
of various intracellular signals (5). 
 
2.1. Type II serine/threonine kinase receptors 
2.1.1. Type II activin receptor (ActR-II) 
 
The mouse type II activin receptor cDNA encodes a 513 aa protein (94). The extracellular ligand 
binding domain with two N-linked glycosylation sites is relatively short compared to receptor 
tyrosine kinases. It contains eight conserved cysteines determining the general fold of this region. A 
cysteine-rich motif found near the transmembrane domain is characteristic to TGF−β receptor 
family members (119). Recently the crystal structure of ActR-II extracellular domain has been 
resolved, and surprisingly, it has seven anti-parallel β-strands that form a three-finger toxin fold 
similar to the folds of several cobra cardiotoxins (120). Mutagenesis studies have shown that three 
hydrophobic amino acid residues predicted to be surface-exposed on the concave face of the ActR-
II are each required for activin A binding (121). 
  
A common feature for serine/threonine (ser/thr) kinase receptors is a single transmembrane domain 
and a cytoplasmic domain with a juxtamembrane region and a kinase domain (Fig. 4). Neural tissue 
specific variant of ActR-II, ActRIIA-N, has a 24 bp insert between the transmembrane region and 
kinase domain suggesting that it may be an alternatively spliced product of the type II receptor gene 
(122). The ActR-II kinase domain has 11 conserved subdomains characteristic of the serine kinases 
(94). The mouse ActR-II gene is encoded by 11 exons and spans over 66 kb (123). It is mapped to 
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chromosomal locus 2q22.3-q23.2 (124). In the 5' region of the gene, no TATA or CCAAT boxes 
are found in the vicinity of the putative transcription start site. However, there are several putative 
transcription factor binding sites that may play important roles in complex transcriptional 
regulation of this gene. 
 
Phylogenetic analysis of the ActR-II compared with other protein kinase sequences revealed that 
ActR-II and a previously identified receptor, Daf-1, from Caenorhabditis elegans (125) constitute a 
separate subfamily of receptor ser/thr kinases. Analysis of type II receptor sequences from various 
species has revealed high evolutionary conservation, with only two aa differences between mouse 
and human sequences, and greater than 90% identity between species as divergent as chicken and 
man (94, 126-128). 
 
Mice deficient in the ActR-II gene (Acvr2) (62) were expected to be a phenocopy of the activin βA, 
βB or βAβB double mutant mice (57, 59). However, they demonstrate only minimal overlap in 
phenotype compared to activin-deficient mutant mice (Table 3). The majority of ActR-II deficient 
mice developed to adults. Suppressed FSH levels and defects in their reproductive performance 
confirm an important role of ActR-II in reproduction. A smaller population of ActR-II-deficient 
mice die at birth or have skeletal and facial abnormalities. The lack of phenotype similarity 
between the ActR-II-deficient mice and the activin deficient mutant mice suggests that other 
ligands in addition to activins may signal through ActR-II. 
2.1.2. Type IIB activin receptor (ActR-IIB) 
 
Subsequently, another ser/thr kinase receptor homologous to the ActR-II was characterized in 
mouse based on the sequence similarity between ActR-II and daf-1 cDNAs (99). The new receptor, 
called ActR-IIB, showed 50-60% identity with ActR-II in the ligand-binding domain and 60-70% 
identity in the kinase domain. Alternative splicing of mouse ActR-IIB mRNA gives rise to four 
different isoforms (Fig. 4). Two of the ActR-IIB isoforms differ from each other by inclusion of a 
24 aa alternatively spliced segment in the cytoplasmic juxtamembrane domain. A second 
alternative splicing event generates two additional isoforms that lack an eight aa proline-rich cluster 
in the external juxtamembrane region. The receptor isoform that includes both segments is 
designated ActR-IIB1 and it codes for a protein of 536 aa. The isoforms that include only the first 
segment or the second segment are designated ActR-IIB2 and ActR-IIB3, respectively, and the 
isoform that lacks both segments is designated ActR-IIB4. The ActR-IIB2 isoform is predominant in 
the mouse. The ActR-IIB isoforms differ in their ligand-binding affinity. Those isoforms that have 
the full extracellular domain sequence have a slightly higher affinity to activin A. Soon after the 
mouse ActR-IIB was published we characterized the human ActR-IIB cDNA, which was found to 
correspond to the mouse ActR-IIB2 isoform (Study I). Subsequently, ActR-IIB1 and ActR-IIB2 
isoforms have been characterized in human teratocarcinoma cells (129). Recently the genomic 
organization of this gene has been resolved. Human ActR-IIB consists of 11 exons and spans about 
30 kb in chromosome 3p22 (124, 130). A unique type of alternative splicing has been observed in 
bovine ActR-IIB. Activin receptor type IIB5 lacks a sequence coding a 14 aa proline-rich region 
located between the transmembrane domain and kinase domain (131) (Fig. 4). 
 
Disruption of the type IIB receptor expression leads to cardiac malformations, defects in axial 
patterning and disturbance of left-right asymmetry in mice (132). Although ActR-IIB deficient 
mice develop to term they die shortly after birth because of complicated heart defects. Among 
human left-right axis malformation cases mutations in ActR-IIB gene are present only rarely (129).  
Gastrulation of mice deficient of both type II receptors, ActRII (Acvr2)-/- x ActR-IIB (Acvr2b)-/-, is 
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severely impaired (133). Hence, type II receptors are suggested to be required for egg cylinder 
growth, mesoderm formation and primitive streak formation (Table 3). 
2.1.3. Other type II serine/threonine kinase receptors 
 
In vertebrates, the type II receptor subfamily includes TGF−β type II receptor (TβR-II) (100), anti-
Müllerian hormone type II receptor (AMHR-II) (107) and BMP type II receptor (BMPR-II) (102-
105). These receptors have been cloned from various species and they share high homology to each 
other. They also exist in alternatively spliced forms. A recently characterized alternatively spliced 
variant of TβR-II, TβR-IIB, with an insertion of 26 amino acids at the N-terminus, is a TGF-β2 
binding receptor (134-136). Alternative splicing of the AMHR results in a 61 aa insertion at the 
same location as TβR-IIB (107). BMPR-II also exists in two different isoforms, one of which has a 
long C-terminal extension that might arise from an alternative splicing (102, 103). Although the 
functional significance of these variants is still unknown, it is interesting that insertions at the N-
terminus of the receptor are only seen in the ligand-binding subunit. 
ligand
binding 
domain
ser/thr
kinase
domain
ligand
binding 
domain
ser/thr
kinase
domain
Figure 4. Schematic representation of activin type II and type I receptors and their 
alternatively spliced variants. The receptors are transmembrane proteins composed of a ligand-
binding extracellular domain with a signal sequence (stippled), a transmembrane domain (dark 
stripes), and a cytoplasmic domain with ser/thr kinase activity. Black boxes indicate 
juxtamembrane alternatively spliced regions or ser/thr-rich C-terminal regions in type II and IIB 
receptors. The white box in the cytoplasmic juxtamembrane region is 14 aa proline-rich sequence 
deleted from ActR-IIB5. In type I receptors, a black box indicates GS-domain or additional C-
terminal tail in ActR-IB2 and ActR-IB3. ActR-IB is alternatively spliced at the kinase subdomains 
VII-XI (striped boxes) generating truncated forms of the receptor. In ActR-IB5 the kinase 
subdomain VII is spliced to subdomain X. 
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2.2 Type I serine/threonine kinase receptors 
2.2.1 Type I activin receptors 
 
A number of additional ser/thr kinase receptors were cloned by PCR using oligonucleotide primers 
based on type II ser/thr kinase receptor sequences. These receptors were initially considered orphan 
receptors because they did not bind activins, inhibins, TGF−βs or BMPs (97). As a result of being 
simultaneously cloned by different groups, most type I receptors have received different names 
before their identity and ligands were established. One practice has been to use the neutral 
nomenclature ALK (activin receptor-like kinase). The first receptor characterized was ALK-2 (also 
known as SKR-1, Tsk7L, R1 and ActX1R) (91, 92, 95-98). It is commonly referred to as type I 
activin receptor (ActR-I) although it is able to mediate only certain activin responses, suggesting 
that there may be other ligands than activins (95, 137-140). Recently it has been demonstrated that 
at least AMH may use ActR-I as its type I receptor (141, 142). The type I activin receptors are 
structurally related to the type II receptor family displaying ser/thr kinase activity. Type I activin 
receptors are slightly smaller than type II receptors displaying a shorter extracellular domain and 
lacking the ser/thr rich C-terminal tail after the kinase domain (Fig. 4) (13). The extracellular 
ligand-binding domains of type I receptors contain seven cysteine residues at nearly invariant 
positions in addition to the cysteine box. A unique feature of type I receptors is a highly conserved 
30 aa region preceding the kinase domain. Because of the characteristic TTSGSGSG sequence this 
region is called the GS domain (115). Ligand-induced phosphorylation of the ser and thr in the GS 
domain of the ActR-IB by type II receptor is required for signal activation (90, 111). Immediately 
following the GS domain, type I receptors have a leu-pro motif that serves as a binding site for the 
cytoplasmic immunophilin FKBP-12 protein (143). Binding of FKBP-12 protects TGF−β type I 
receptor against phosphorylation, thus preventing the spontaneous, ligand-independent activation of 
type I receptor by type II receptor in vitro (11, 144). 
 
The predominant type I activin receptor in mammalian cells is ActR-IB (ALK-4) (13, 91, 92, 101). 
A study of the ActR-IB gene predicted several possible mRNA species, generated by alternative 
splicing (145). The full length ActR-IB (ALK-4) has eleven kinase subdomains (I-XI) and is called 
ALK4-1. ALK4-2 lacks almost completely the kinase subdomain XI and ALK4-3 lacks 
subdomains X and XI, but both have a carboxy-terminus with novel sequences not found in ALK4-
1. ALK4-4, the most truncated splicing variant, lacks kinase subdomains IX-XI and part of the 
subdomain VIII. ALK4-5 is identical to ALK4-4, except for the addition of a ser and pro at its 
carboxy-terminus (146) (Fig. 4). Activin type I and IB receptors are in different subgroups within 
the ALK family (Table 2). The extracellular domains share little sequence identity between ActR-I 
and ActR-IB and the distribution of mRNA expression of these two receptors in various tissues is 
distinct (91, 92). However, the kinase domain of the type I and type IB activin receptors are over 
60% homologous to each other. Human ActR-I (Acvr1) and ActR-IB (Acvr1b) genes have been 
localized to chromosomes 2q23-q24 and 12q13, respectively (147). 
 
The genomic structure of the mouse ActR-I has been resolved (148). The mouse ActR-I gene 
consists of 10 exons of which the first one is not translated. According to primer extension studies, 
alternative transcription start sites might be used for expression of the mouse ActR-I gene resulting 
in variable size of the 5' untranslated region. The roles of ActR-I and IB in activin signalling have 
been studied by gene targeting in mice (Table 3) (149-151). ActR-I is required for gastrulation and 
ActR-IB functions in organizing the egg cylinder before gastrulation and primitive streak formation 
indicating that activin type I receptors mediate signals required for early embryonic development. 
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Table 3. Targeted inactivation of activin receptors 
 
Transgenic mouse model Phenotype       References  
 
ActR-II-/-    viable        (62) 
(Acvr2-/-)     infertility in females 
delayed fertility in males 
      small gonads 
      mandibular defects  
 
ActR-IIB-/-    postnatal lethality      (132) 
(Acvr2b-/-)    cardiovascular, splenic and renal defects 
      disturbance of left-right asymmetry 
      defects in axial patterning 
 
ActR-II-/- x ActR-IIB-/-   embryonic lethality     (133) 
 
ActR-I-/- embryonic lethality     (149, 150) 
(Acvr1-/-) 
ActR-IB-/-    embryonic lethality     (151)  
(Acvr1b-/-) 
 
2.2.2.  Other type I serine/threonine receptors 
 
Presently, seven different type I receptors are known. They can be classified into two different 
groups according to which downstream signalling proteins, Smads, they are connected with (see 
chapter 2.4). ActR-IB, TGF−β type I receptor (ALK-5, XTrR-I) (106, 152) and ALK-7 (109, 110) 
acting as the type I receptor for mouse Nodal and Xenopus nodal related protein-1 (Xnr-1) (153) 
form the first group. ActR-I, BMP type I and IB receptors (ALK-3 and ALK-6) (91, 92, 108, 118) 
and ALK-1 (also known as TSR-I), which participates in TGF−β signalling in endothelial cells (9, 
154), form the other group. 
2.3. Ligand-receptor interactions and mechanism of receptor activation 
 
In the case of activin A both type I receptors (ActR-I and ActR-IB) are able to form complexes 
with type II activin receptors (ActR-II and ActR-IIB) (95, 98, 101). Further, it has been suggested 
that ActR-IB, but not ActR-I, mediates growth-inhibitory and extracellular matrix responses in 
concert with activin type II receptors (101). Thus, activin A may induce distinct cellular responses 
depending on which particular receptors are expressed in the cell. The diversity of cellular 
responses to different TGF−β ligands may be accounted for by the type I receptors (Table 3). 
Interestingly, it has been observed that in the presence of ActR-II both BMP-7/OP-1 and GDF-5 are 
able to use BMPR-IB and ActR-I, respectively, for signal transduction (118, 138, 155). On the 
other hand, BMP-7/OP1 and BMP-2 can induce a transcriptional response via a BMPR-II-ActR-I 
receptor complex (103). BMP-2 is also able to signal either by a BMPR-II-BMPRI/BMPR-IB or an 
ActR-IIB-BMPR-I/BMPR-IB complex (156). In Xenopus embryo explant experiments 
constitutively active ActR-I mimics the mesoderm ventralizing activity of BMP-4, which suggests 
that ActR-I may function as a BMP receptor in vivo (137). As activin does not have any BMP-like 
effects, it is conceivable that ActR-I is not a real activin receptor but rather a receptor mediating 
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BMP signals. Inhibin also binds to ActR-II (94) sharing the same binding site with activin A on 
ActR-II (121). According to current knowledge, after binding to cell surface betaglycan co-
receptor, inhibin binds to ActR-II, preventing activin from binding to ActR-II and thereby 
antagonizing the activin signal (Fig. 5) (157). 
 
Table 3. Mammalian TGF−β family member ligands and their receptors 
 
Ligand    Receptor II    Receptor I    
 
Activin    ActR-II     (ActR-I) (ALK-2) 
     ActR-IIB    ActR-IB (ALK-4)   
TGF-β     TβR-II     TβR-I (ALK-5) 
           ALK-1 
           (ALK-2) 
                                                                      (ALK-7)     
BMP-2    BMPR-II    BMPR-I (ALK-3) 
BMP-4    ActR-II     BMPR-IB (ALK-6) 
BMP-7/OP-1   ActR-IIB    ActR-I 
GDF-5         _______________________ 
Nodal    ActR-II     ALK-7 
     ActR-IIB    ActR-IB     
AMH    AMHR-II    ActR-I     
           BMPR-IB    
GDF-9    BMPR-II    ?      
 
2.4. Intracellular signalling of activin 
 
The proteins of the SMAD family are so far the only identified substrates for type I receptor ser/thr 
kinases (Fig. 5). Three functionally distinct subfamilies of Smads have been defined: receptor-
regulated Smads (R-Smads: Smad1, Smad2, Smad3, Smad5 and Smad8), the common-mediator 
Smads (co-Smads: Smad4) and the antagonistic or inhibitory (I-Smads: Smad6 and Smad7) [for 
review see Attisano et al., Itoh et al., Massagué and Chen, ten Dijke et al. and Roberts and Derynck 
(10, 12, 139, 158, 159)]. Activin receptor complexes activate the Smad pathway by interacting and 
phosphorylating specific R-Smads, Smad2 and Smad3. Phosphorylation of R-Smads dissociates 
them from the activin receptors and leads to formation of complexes with co-Smad. Thereafter, the 
Smad complex is translocated to the nucleus, where it binds to DNA and associates with 
transcription factors such as the forkhead activin signal transducer (Fast) (160) and Jun (161). 
Antagonistic Smad7 inhibits the binding of R-Smads to the receptor subunits by competing for the 
receptor interaction and marking the receptors for degradation. Like TGF−β superfamily ligands 
and receptors the Smad family is highly conserved and the homologues of these classes have been 
identified in X.laevis, D.melanogaster and C.elegans. 
 
Identification of several Smad-associated proteins has provided new insights into how Smad 
activity is controlled. In the activin signalling cascade Smad/receptor accessory protein, Smad 
anchor for receptor activation (SARA), facilitates binding of Smad2 to the heteromeric activin 
receptor complex. The stable interaction of SARA with non-phosphorylated Smad2 also prevents 
nuclear import of Smad2 (162). Newly described activin receptor-interacting protein-1 associates 
with ActR-II and with Smad3, enhancing Smad3-mediated signalling in response to activin (163, 
164). Activin receptor-interacting protein-2 interacts with both ActR-II and ActR-IIB and enhances 
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endocytosis of ActR-IIs, suppressing activin-induced transcription (165). The nature of these 
interactions appears to determine whether Smads positively or negatively regulate activation of 
target genes (158, 164). 
 
Although Smads are central elements in the activin signal transduction pathway, activin is also able 
to activate the p38 mitogen-activated protein kinase (MAPK) pathway (166). Phosphorylation of 
p38 MAPK leads to phosphorylation of ATF2 transcription factor and growth inhibition of breast 
cancer cell lines in vitro. 
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Figure 5. A simplified model for transducing activin signals into the cells. The binding of 
activin to type II receptors induces the phosphorylation of the type I receptors. Activated receptor 
complex leads to phosphorylation of Smad2 and Smad3 that permits the interaction with Smad4 
and translocation of this complex to the nucleus. In the nucleus Smad-complex regulates specific 
gene promoters through the interaction with Smad-specific binding site (SBS) and specific 
coregulators. SARA interacts with Smad2 and the receptor complex and assists in the 
phosphorylation of Smad2 by the type I receptor. Negative regulation is provided by different 
growth factor-sequestering proteins. Follistatin or FSRP binds activin by inhibiting its interaction 
with activin receptors. In the presence of betaglycan inhibin competes with activin for the binding 
to type II receptors. Smad7, in turn, inhibits the activation of Smad2 and Smad3, thereby blocking 
the activin signalling pathway. BAMBI, which is structurally related to type I receptors, lacks the 
intracellular kinase domain. Acting as a pseudoreceptor, it prevents homodimerization of type I 
receptors. (adapted from Findlay et al. (167). 
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3.  Expression and regulation of activin/inhibin subunits, follistatin and activin 
receptors 
 
3.1. The tissue distribution of activin/inhibin subunits, follistatin and activin type I and II 
receptor mRNAs 
 
For many years the primary information available for activins and its receptors has mainly been the 
expression pattern in different cells and tissues. Although activins were initially isolated as gonadal 
proteins, the expression of their mRNAs has been detected in a number of extragonadal tissues in 
all germ layers of fetal and adult tissues. Table 2 presents the distribution pattern of activin and 
inhibin subunits, activin receptors and FS mRNA expression in adult murine tissues from 
references (4, 91, 94, 97, 98, 122, 145, 168-174) and http://www.ncbi.nlm.nih.gov/UniGene/. 
 
Table 2. Tissue distribution of inhibin and activin subunits, FS and activin receptor 
transcripts in adult murine tissues. 
 
Tissue   α βA βB FS ActRII ActR-IIB ActR-I ActR-IB 
 
Ovary   + + + + +    +   +   + 
Testis   + + + + +    +   +   ? 
Pituitary   + - + + +   +   +   ? 
Adrenal    + + + + ?   ?   ?   ? 
Brain   + + + + +   +   +   + 
Bone marrow  - + - + ?   ?   ?   ? 
Spleen   + + - - ?   ?   +   + 
Placenta   + + + - +  +   ?   ? 
Heart   ? ? ? + +    +   +   + 
Lung   ? ? ? + +    ?   +   + 
Thymus   + ? + + +  +   +   + 
Skeletal muscle ? ? + + ?    ?   ?   + 
Uterus/decidua - + - + +   +   ?   ? 
Kidney   + - - + ?   ?   +   + 
Pancreas   + + + + +    +   +   ? 
Liver/hepatocytes + + - ? +  ?   +   + 
 
 
3.2. Expression and regulation of activin subunit and activin receptor mRNAs in the 
ovary 
 
Inhibin and activin have important roles in folliculogenesis, oocyte maturation and in corpus 
luteum function in rodents and primates. In the rat ovary inhibin and activin subunit mRNAs are 
expressed in granulosa cells of growing follicles (8). The expression patterns and regulation of the 
mRNAs by a variety of hormones and growth factors have been well documented (175, 176). In the 
human ovary, βA-subunit mRNA expression is found in the granulosa cells and the corpus luteum 
whereas the βB-subunit messenger is detected in the granulosa cells of small antral follicles but not 
in dominant follicles or the corpus luteum (177). Activin A protein is present exclusively in the 
granulosa cells of mature follicles and in the corpus luteum (178). 
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Many studies have demonstrated that activin A has a direct effect on the synthesis of many ovarian 
hormones. Activin-induced proliferation has been observed in cultured rat granulosa cells from 
both small and large follicles (179, 180) and in human granulosa luteal (GL) cells (181), suggesting 
a role for activin in early follicular development. Activin A also increases inhibin α-subunit 
transcription and protein biosynthesis in cultured rat granulosa cells (182). Sites of activin 
production are widespread and often overlap with their sites of action, suggesting paracrine or 
autocrine role in reproduction. 
 
The expression of activin receptor genes has been detected in ovarian follicles. In ligand binding 
studies activin A binds to the granulosa cells during all phases of the rat ovarian cycles (183). 
Expression of the activin receptor type II and IIB mRNAs has also been detected in ovarian 
granulosa cells, corpus luteum and oocytes of mouse, rat and human (172, 184). The presence of 
four activin receptor subtypes has been demonstrated in human granulosa cells and oocytes as well 
as in postnatal rat ovary (173, 184). Recently, the expression of ActR-II and IIB proteins in human 
follicles has been confirmed by immunohistochemistry (185). 
 
3.3. The effects of activin A in normal erythropoiesis and in erythroleukemia cells 
 
Several lines of evidence indicate that activin A functions as a physiological regulator of erythroid 
lineage cells. Erythroid differentiation factor (EDF) was first found in the conditioned medium of 
12-O-tetradecanoyl-phorbol-13-acetate (TPA)-stimulated human monocytic leukemia cells, based 
on its ability to induce erythroid differentiation of murine Friend erythroleukemia cells (186). 
Later, EDF was found to be identical to human activin A (7). Early studies indicate that in the 
presence of erythropoietin, activin A promotes the colony formation of early (187, 188) and late 
stages (189) of erythrocyte differentiation in the bone marrow cell cultures. It drives immature 
erythroid precursors to form hemoglobinized cells, thereby rendering the colonies recognizable as 
erythroid colonies (189-191). Purified erythroid progenitor cells also possess receptors for activin 
on their surface (191). Recently, it has been observed that activin A commits the erythroid 
progenitor cells to apoptosis without erythropoietin costimulation required for further maturation 
(192). Activin enhances proliferation of normal erythroid precursor cells not only in culture 
systems but also when administered to rodents in vivo (193, 194). Endogenous activin A production 
by bone marrow cells supports the importance of activin A in regulating erythropoiesis (195-197). 
 
Human K562 cells, derived from a patient with chronic myelogenous leukemia with the BCR/ABL 
oncogene of the Philadelphia chromosome translocation (198), provide a model system for 
studying erythroid differentiation. The addition of activin A to K562 cells causes them to become 
hemoglobin positive and inhibits their proliferation (189). Further, the accumulation of globin 
transcripts is induced by activin A (199). It has been indicated that the K562 cells possess specific 
binding sites for activin on their surface (16). Both type II activin receptors and activin receptor 
type IB are required for activin-induced transcriptional activity (200). Moreover, by using an 
inducible promoter the levels of ActR-IB and ActR-II can be increased, which enhances the effects 
of activin on erythroid differentiation (201). The treatment of K562 cells with TPA leads to loss of 
erythroid properties. Although the K562 cell line is not an ideal model for megakaryoblastic 
differentiation, several megakaryoblastic characteristics, such as TGF−β expression, can be 
detected by TPA induction (202, 203). 
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Aims of the present study 
 
 
The aim of the present study was to investigate where human activins and their signalling 
components are expressed, and how they are regulated in different activin responsive cell models as 
well as in human developing tissues. 
 
The specific aims of the study were to determine: 
 
- the primary structures of  human type II activin receptors  
 
-  the distribution of the activin β-subunits, follistatin and type II activin receptor transcripts in 
human developing tissues  
 
- the expression and regulation of activin and inhibin subunits and activin receptor transcripts 
in human granulosa-luteal cells  
 
- the regulation of activin βA-subunit and activin receptor transcripts in human 
erythroleukemia K562 cells  
 24
Materials and methods 
 
1. Cell cultures 
 
Human K562 [CCL-243; American Type Culture Collection (ATCC), Rockville, MD, USA] and 
HL-60 cells (CCL-240; ATCC) were grown in RPMI 1640 medium supplemented with 10% fetal 
calf serum (FCS; GIBCO Laboratories, Grand Island, NY, USA). Mouse NIH-3T3 fibroblasts 
(CRL-1658; ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO) 
supplemented with 10% newborn calf serum (NCS), 2 mmol/l L-glutamine, 100 IU/ml penicillin, 
and 100 µg/ml streptomycin (GIBCO) at 37ºC in a humified 95% air-5% CO2 atmosphere. The 
experiments were performed in RPMI 1640 medium or DMEM supplemented with 1% FCS or 
NCS. Human GL cells were aspirated from women undergoing hormone treatment for in vitro 
fertilization. For each experiment, the cells from two to four patients were pooled and 
enzymatically dispersed and separated from red blood cells by centrifugation through Ficoll-Paque 
(Pharmacia, Uppsala, Sweden), as previously described (204). They were plated at a density of 2-5 
x 105 cells/well in 35-mm six-well dishes (Costar, Cambridge, MA) and cultured in DMEM 
(GIBCO) supplemented with 10% FCS, 2 mM L-glutamine, and antibiotics (100 IU/ml penicillin, 
100 µg/ml streptomycin, and 0.25 µg/ml amphotericin-B; GIBCO). Cell culture media were 
changed every other day, and hormone treatments were performed on days 2 to 7 of culture. Prior 
to hormone treatments the human GL cells were transferred to DMEM medium supplemented with 
2.5% FCS and antibiotics.  
2. Treatments of the cell cultures 
 
For megakaryocytic differentiation, K562 cells were induced with increasing concentrations of 
TPA [0.003 to 100 ng/ml; Sigma Chemical Co, St Louis, MO, USA; dissolved in dimethyl 
sulfoxide (DMSO)] (203, 205). For erythroid differentiation, K562 cells were treated with 
recombinant human activin A (189) (0.1 to 30 ng/ml; a gift from Dr. Y. Eto, Ajinomoto Co, 
Kawasaki, Japan) or TGF−β (1 ng/ml; R&D Systems, Minneapolis, MN, USA). To study the effect 
of cyclic AMP (cAMP) on βA-subunit mRNA levels the K562 cells were treated with the cell 
permeable cAMP analog, 8-bromo-cAMP (8-Br-cAMP; 1 mM; Sigma). The K562 cells were also 
treated with protein kinase inhibitor H7 (10 µM; Seigaku America, Inc., St. Petersburg, FA, USA) 
(76) with or without TPA (10 ng/ml). HL-60 cells were induced to either monocyte/macrophage or 
granulocyte-like cells by 10 ng/ml TPA or 1.2% DMSO, respectively (206). 
 
To study the regulation of inhibin subunits, the GL cells were treated with different concentrations 
of activin A (0.3 to 100 ng/ml) for indicated time periods. To test the effect of recombinant human 
follistatin (288-aa follistatin, generously provided by Dr. Raiti, University of Maryland School of 
Medicine, Baltimore, MD) on basal and activin A-stimulated βB-subunit mRNA expression, 
increasing concentrations of follistatin (4-700 ng/ml) were first incubated with or without 50 ng/ml 
activin at 37ºC for 1 h in 50 ml phosphate buffered saline (PBS) containing 0.1 %  bovine serum 
albumin (BSA) before given to the cells in 2 ml DMEM-2.5% FCS for 24 h. To study the effect of 
human chorionic gonadotropin (hCG) alone (CR-127 preparation was donated by the National 
hormone and pituitary programme, NIDDK, NIH) or in combination with activin A, the cells were 
stimulated with 100 ng/ml hCG and/or 60 ng/ml activin A for 24 or 48 h. Purified bovine inhibin A 
was from Peninsula Labs Europe (Merseyside, UK). 
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3. Human fetal tissues 
 
Human fetuses were obtained from the Helsinki Maternity Clinic by approval of the hospital's 
ethics committee and by informed consent of the mother undergoing legal abortion. The gestational 
ages varied from 15-17 weeks as estimated from fetal foot lengths (207). Tissues were dissected 1-
4 h post-mortem and rapidly frozen in liquid nitrogen for storage at –70ºC prior to RNA extraction. 
4. RNA extraction and blotting 
 
Total RNA was isolated from K562 and HL-60 cells and human fetal tissues by the guanidinium 
isothiocyanate/CsCl method (208). Polyadenylated RNA was isolated from total K562 and NIH-
3T3 cell RNA as well as human fetal brain tissue by a PolyATtract System IV kit (Promega, 
Madison, WI, USA). The modified Nonidet P-40 lysis method (209) was used for extracting 
cytoplasmic RNA from human GL cells, K562 cells and NIH-3T3 fibroblasts. The RNAs were 
quantitated by absorbance at 260 nm. For Northern blots, 3.9 micrograms of glyoxylated 
polyadenylated RNA or 10 µg of total RNA samples were size-fractioned in 1.5% agarose gels, and 
transferred to Hybond-N nylon membranes (Amersham International, Aylesbury, Buckinhamshire, 
UK). For dot blots, 1-2 µg of cytoplasmic RNA was denatured and spotted onto nylon membranes 
using a 96-well Minifold device (Schleicher and Schuell, Keene, NH, USA). The RNA blots were 
baked for 1-2 h at 80ºC and thereafter UV cross-linked for 6 min with a UV illuminator (Reprostar 
II, Camag, Switzerland). 
5. RT-PCR, cDNA cloning and sequencing 
 
Reverse transcription-polymerase chain reactions (RT-PCR) were performed according to 
previously described protocols (210). One microgram of total RNA from the adequate tissue source 
was used for cDNA synthesis. The 10 µl reaction volume contained 100 U Moloney murine 
leukemia virus reverse transcriptase (Bethesda Research Laboratories [BRL], Gaithersburg, MD), 
0.2 µg oligo d(T)15 primer (Boehringer Mannheim, Mannheim, Germany), 2 µl of 5 X RT buffer 
(BRL), the four dNTPs (at 0.5 mmol /l final concentration of each; Perkin-Elmer Cetus Corp, 
Norwalk, CT), and 5 U human placental RNAse inhibitor (Amersham) at 37ºC for 60 min. 
 
One microliter of the RT mixture was subjected to PCR, which was performed according to the 
instructions provided with the GeneAmp DNA Amplification Reagent Kit (Perkin-Elmer, Cetus). 
The primers for amplification of full length ActR-II and ActR-IIB were designed according to 
published rodent sequences (94, 99, 211), and are listed in Table 1 (I). Amplification of K562 cell 
cDNA with primers no. 7 and 8 yielded a 556-bp DNA product homologous to mouse ActR-II 
sequence. Primers no. 1 and 2 were used for amplification of a 959-bp human ActR-IIB fragment 
from the same cDNA. These fragments were used as hybridization probes to screen Northern blots 
of human fetal tissue RNA samples. For obtaining the full open reading frame of human ActR-II 
and ActR-IIB, we used human fetal kidney and brain cDNA, respectively, to amplify the missing 5’ 
and 3’ sequences. The amplification conditions consisted of initial denaturation at 94ºC for 2 
minutes followed by 45 cycles of amplification with denaturation at 94ºC for 30 seconds, annealing 
at 55ºC for 30 seconds and extension at 72ºC for 1 minute and 30 seconds. 
 
All probes used in hybridization analysis were produced by the RT-PCR. Amplification of activin 
βA-subunit and β-actin fragments was performed with previously described specific oligonucleotide 
primers using untreated granulosa-luteal cell RNA as a template (41). Human ActR-I, ActR-IB, 
TGF−β and α-globin amplification, the cDNA cloning procedure and primers used for PCR are 
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detailed in Studies I and III. The primers used for inhibin α- and βB-subunit and the cDNA clones 
obtained have been described elsewhere (36, 42). A genomic 417-bp DNA fragment for the activin 
βC-subunit was derived by PCR performed on human K562 cell DNA (212). 
 
The amplified cDNAs were ligated to commercial T-vectors pCR1000 (InVitrogen, San Diego, 
CA, USA) or pGEM-T (Promega) and characterized by sequencing the double stranded plasmid 
templates using cloned T7 DNA polymerase (Sequenase 2.0, U.S. Biochemical Corp., Cleveland, 
OH, USA). 
6. Southern blotting 
 
For Southern blotting of amplified cDNA fragments, the samples were electrophorezed through 3.5 
or 4% agarose gels, stained with ethidium bromide and illuminated under UV light. The samples 
were then transferred on Hybond N nylon membranes (Amersham) according to standard protocols 
(213) or by the downward alkaline capillary transfer method (214).  
7. Probe labeling, hybridizations and quantification of the data 
 
Double stranded cDNA inserts were labeled with [α-32P]deoxy (d)CTP (3000Ci/mmol; DuPont, 
Boston, MA, USA or Amersham) by the random priming method (Random priming (30) labelling 
kit; Boeringer Mannheim or Prime-a-gene kit; Promega). If the signal was weak single stranded 
cDNA probes were prepared by linear PCR amplification. Both single- and double-stranded cDNA 
probes were purified with Nick columns (Pharmacia Biotech, Uppsala, Sweden) or NucTrap 
columns (Stratagene, La Jolla, CA) and used at 1-3 x 106 cpm/ml in hybridization solution 
containing 50% formamide, 6 X SSC (1 X SSC = 0.15 M NaCl and 0.015 M Na-citrate, pH 7.0), 
0.1% Ficoll, 0.1% polyvinylpyrrolidone, 0.1% BSA, 100 µg/ml salmon sperm DNA, 100 µg/ml 
yeast RNA, and 0.5% sodium dodecyl sulfate (SDS). Northern and Southern blots were hybridized 
for 16 h at 42ºC and washed three times for 20 minutes with 1 X SSC-0.1% SDS at 55ºC. Filters 
were exposed to X-ray film with Trimax 16T intensifying screens (3M, Ferrania, Italy) at –70ºC. 
The relative densities of dot blot hybridization signals were detected using transmission 
densitometer (model 331, X-rite Co., Grand Rapids, MI). Alternatively, hybridized filters were 
analyzed by Fujifilm IP-reader Bio-Imaging Analyzer BAS 1500 (Fuji Photo co. Ltd., Tokio, 
Japan) with the MacBas software supplied by the manufacturer. 
8. Analysis of RNA data 
 
For single comparisons the data were analysed by the Student's t-test. For multiple comparisons the 
data were first analysed by one-way analysis of variance, and statistical significance was 
determined by Scheffe's multiple comparison test using the Exstatics program (Select Micro 
Systems, Yorktown Heights, NY) on a Macintosh personal computer. 
9. Western blotting 
 
For Western analysis the culture media were concentrated with Ultrafree MC 10.000 NMWL filter 
unit concentration tubes (Millipore Products Division, Bedford, MA, USA). Duplicate 30 ml 
aliquots equivalent to 800 µl of medium were run under reducing and non-reducing SDS-
polyacrylamide gel electrophoresis (PAGE) conditions and transferred to Hybond-C extra 
nitrocellulose filters (Amersham) using a Bio-Rad Mini Trans-Blot apparatus (Bio-Rad 
Laboratories, Richmond, CA, USA). Before immunoblot analysis the membranes were incubated in 
blocking solution [Tris buffered saline (TBS), 3% BSA] at room temperature for 1-2 hours. 
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Subsequently, the blots were exposed to a 1:500 dilution of rabbit polyclonal βA-antiserum (#560) 
(41) or to a 1:2000 dilution of mouse monoclonal E4 anti-βA antibody (Serotec, Oxford, UK) and 
incubated at +4 C overnight. As negative controls, the polyclonal βA-antiserum was pre-incubated 
with synthetic βA (93-105)-NH2 peptide (50 µg/ml) and the mouse monoclonal E4 antibody was 
pre-incubated with activin A (250 ng/ml) overnight at +4 C prior to incubation with membranes. 
The blots were then rinsed with the TBS/Tween buffer and incubated with peroxidase conjugated 
goat-anti-rabbit IgG or goat-anti-mouse IgG (1:3000) (Bio-Rad). The immunoreaction was detected 
using Enhanced Chemiluminescence (ECL) system according to the manufacturer's instructions 
(Amersham). 
10. Radioiodination of follistatin and ligand blotting 
 
Activin binding protein, follistatin 288, obtained from the National Institute of Child Health and 
Human Development, NIH, was iodinated using the Iodo-Gen method according to manufacturer's 
instructions (Pierce, Rockford, IL, USA) and the labelled protein was purified by PD10 columns 
(Pharmacia). The proteins in the culture media of unstimulated and TPA-induced cells were 
separated on SDS-PAGE and transferred onto nitrocellulose filters. The filters were incubated with 
125I follistatin (200 000 cpm/ml) overnight at +4ºC (76), washed with the TBS/Tween buffer and 
exposed to X-ray film for 1 to 3 days at –70ºC. As a specificity control, 125I-labeled follistatin was 
pre-incubated with activin A (250 ng/ml) overnight at +4ºC prior to incubation with membranes. 
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Results  
 
1. The primary structure of human activin receptor type II and IIB (I) 
 
Human ActR-II and ActR-IIB cDNAs were amplified by RT-PCR using primers designed 
according to published rodent ActR-IIs sequences. The 556-bp and 959-bp fragments of ActR-II 
and ActR-IIB, respectively, were amplified from human K562 cell cDNA covering part of the 
extracellular domains, transmembrane regions and part of the intracellular kinase domains. Since 
type II activin receptors were expressed at relative low levels in K562 cells we delineated the tissue 
distribution pattern of ActR-II and ActR-IIB mRNAs in other sources to facilitate their cloning. A 
strong expression level of ActR-II was detected in human fetal kidney. The expression of ActR-IIB 
was highest in the developing brain. Therefore, human fetal kidney and brain cDNAs were used to 
amplify RT-PCR clones representing the missing 5' and 3' sequences to obtain the full reading 
frame of hActR-II and hActR-IIB, respectively. 
 
To evaluate the possible alternative splicing of hActR-IIB mRNA, RT-PCR was performed on 
human K562 cells and human fetal brain polyadenylated mRNAs and mouse NIH-3T3 cell RNA 
using primers flanking the region of the cDNA encompassing the alternative spliced regions. 
Southern hybridization with the 544-bp hActR-IIB2 probe defined only a fragment corresponding to 
the ActR-IIB2 isoform. This fragment was amplified from K562 cell and human fetal brain cDNA. 
However, under similar experimental conditions, the four mouse splicing variants were detected in 
Balb/c 3T3 fibroblast cDNA (99). In NIH-3T3 cells the ActR-IIB2 isoform was clearly more 
abundantly expressed than the other three variants. 
 
2. The tissue distribution of inhibin α, activin βA- and βB-subunit, follistatin and ActR-
II and -IIB messenger ribonucleic acids in human fetal tissues (I and II) 
 
During human development only the adrenal glands expressed the 1.6-kb inhibin α-subunit 
transcripts. The strongest expression of the βA-subunit was detected in neural and muscular tissues. 
These 1.7-, 4.0- and 6.0-kb βA-subunit transcripts were also detected in several exocrine tissues as 
well as in bone marrow. The 3.8- and 4.8-kb transcripts of the βB-subunit were also detected in 
most of these tissues but the expression levels differed compared to the βA-subunit. The βB-subunit 
transcripts were most abundant in neural tissues, adrenal glands and salivary glands. The major 2.5-
kb and the minor 1.5-kb transcripts of follistatin were seen in several fetal tissues with the highest 
expression levels in the kidneys, the liver and skeletal muscle. 
 
Similar to activin β-subunit mRNAs, the highest expression levels of the 3.0- and 6.0-kb ActR-II 
and 2.5- and 10-kb ActR-IIB transcripts were detected in developing neural tissues such as 
cerebrum and spinal cord. Moderate expression levels of both ActR-II and ActR-IIB were detected 
in muscular tissues such as skeletal muscle, heart and stomach. Low but detectable expression of 
ActR-IIB mRNA was also observed in several glandular tissues (kidney, salivary, and pancreas) 
and hematopoietic tissues (spleen, liver, thymus, and bone marrow). The adrenal glands, which 
consists of both glandular (cortex) and neural (medulla) tissue, also expressed ActR-IIB mRNA. 
Although ActR-II and ActR-IIB mRNAs were coexpressed in several human fetal tissues ActR-IIB 
showed a wider tissue distribution than ActR-II. 
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3. Expression and regulation of βΑ-subunit transcript and polypeptide, and type I and 
II receptor mRNAs in K562 cells (I and IV) 
 
In Northern analysis of untreated K562 cell RNA no hybridization signal of βA-subunit mRNA was 
detected. However, βA-subunit transcripts of 1.8-, 2.8-, 3.0-, 4.3-, and 6.4-kb were seen in TPA-
stimulated K562 cells. The expression of βA-subunit mRNA was also confirmed by RT-PCR 
analysis. A 786-bp fragment was amplified from TPA-induced K562 cells whereas no 
amplification product was seen in untreated cells. As a positive control for βA-subunit primers 
granulosa-luteal cell RNA was used as a template. No transcripts for the inhibin α-, activin βB- or 
βC-subunits were detected by RT-PCR followed by Southern blotting of the PCR products of 
untreated or TPA-treated K562 cells (data not shown). 
 
TPA regulates the expression of βA-subunit transcript in both a time- and concentration dependent 
manner in K562 cells. The induction of the βA-subunit transcripts with 10 ng/ml TPA was seen 
after eight hours incubation, and the maximal responses were obtained with 1.0-100 ng/ml of TPA. 
In contrast neither activin nor TGF-β, which differentiate K562 cells toward the erythroid lineage, 
stimulated βA-subunit mRNAs (data not shown). The induction of activin βA-subunit mRNA 
expression by TPA could be blocked with a potent protein kinase C inhibitor H7 (10 µM). 
 
In Western blot analysis we used the reduced samples of culture medium of K562 cells treated for 
72 h with 10 ng/ml of TPA. Polyclonal βA-antibody (#560) detected a 14 kD protein in these 
samples. The immunoreaction was prevented by pre-incubation of the polyclonal anti-βA antiserum 
with the synthetic βA peptide against which the antibody was raised confirming the specificity of 
the βA-antibody. The monoclonal E4 anti-βA antibody was used to recognize dimeric βA-subunits. 
The predicted 25 kD protein was recognized in the culture medium of TPA-treated K562 cells 
whereas no signal was detected when the E4 βA-antibody was pre-incubated with activin A. The 
follistatin binding capacity of the 25 kD protein was determined by ligand blotting experiments 
with 125I-labelled activin-binding protein follistatin. A 25 kD protein was consequently detected in 
conditioned medium of TPA-treated K562 cells. Pre-incubation of 125I-follistatin with activin A 
prior to ligand blotting prevented the recognition of the 25 kD protein confirming the specificity of 
the signal. To determine the time- and concentration dependence of the effect of TPA on activin A 
protein secretion K562 cells were also used in Western and ligand blotting analyses. Our results 
indicate that βA-subunit monomers and dimers become detectable in the culture medium after a 24 
h stimulation with 10 ng/ml of TPA and that maximal levels are reached by 48 h. Concentration 
dependence experiments indicated that TPA concentrations of 1.0 ng/ml, and above, strongly 
induced the secretion of activin A in these cells. 
 
The expression of activin type II and type I receptor transcripts were studied by Northern blot 
analysis of polyadenylated K562 cell RNAs. The specific 10- and 2.5-kb transcripts and a very 
weak 2.1-kb hybridization signal were observed with the ActR-IIB probe. For ActR-II, 6.0- and 
3.0-kb transcripts were detected. The expression levels of both type II receptors were relatively low 
in K562 cells when compared with eg. human fetal brain. Although no exact quantitative 
determination of mRNA levels was performed, ActR-IIB appeared to be more abundantly 
expressed than ActR-II in K562 cells based on the comparison of hybridization signals obtained 
after similar exposure times of Northern blots. 
 
The regulation of ActR-II and ActR-IIB mRNA levels during the differentiation of K562 cells was 
studied by Northern blot and dot blot hybridization. The K562 cells were treated with increasing 
concentrations of activin A (0.1 to 30 ng/ml) for 72 hours for erythroid differentiation. Activin A 
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increased α-globin mRNA expression in K562 cells in a concentration- and time- (data not shown) 
dependent manner. However, neither ActR-II nor ActR-IIB mRNA levels were affected by activin 
A treatment. On the other hand, during TPA-induced (0.01 to 10 ng/ml) megakaryocytic 
differentiation the expression of TGF-β1 mRNA was stimulated in a concentration-dependent 
manner in K562 cells although it had no effect on ActR-II and ActR-IIB mRNA levels. The relative 
expression levels of both ActR-II and ActR-IIB mRNAs were not altered by induced 
differentiation. 
 
For ActR-I and ActR-IB the specific 4.0-kb and 5.2-kb transcripts were detected. Both type I 
activin receptors were relatively weakly expressed in untreated K562 cells, but induction with TPA 
(10 ng/ml) increased their expression in a time-dependent manner. However, neither ActR-I nor 
ActR-IB mRNA levels were affected by activin A (20 ng/ml) or TGF-β1 (1 ng/ml) treatments. 
 
Since 8-Br-cAMP has been shown to increase βA-subunit mRNA levels in several different human 
cell culture models we determined whether it affects βA-subunit and type I activin receptor mRNA 
expression in K562 cells. Neither βA-subunit nor type I activin receptor transcript levels were 
induced by 8-Br-cAMP (1 µM). Interestingly, the effect of TPA on βA-subunit mRNA expression 
was significantly increased when the K562 cells were treated with TPA (10 ng/ml) and 8-Br-cAMP 
(1 µM) together. However, TPA-induced type I activin receptor mRNA levels were not affected by 
a co-treatment with 8-Br-cAMP. 
 
4. Regulation of α-, βA- and βB-subunit and activin receptor mRNAs in human GL-cells 
(III) 
 
Northern analysis of activin A (30 ng/ml) treated human granulosa-luteal cells showed that the 
expression of a specific 4.8-kb βB-subunit mRNA was induced within 24 h whereas the expression 
of the 1.6-kb α-subunit or β-actin transcripts (used as a loading control) were not affected. No 
effect on the βA-subunit mRNAs was detected (data not shown). Dot blot hybridization experiments 
indicated that the α- and βA-subunit transcripts were not induced by activin A at any time point 
between 2-48 h. By contrast, after 8 h stimulation with activin A the expression levels of βB-subunit 
mRNAs were significantly increased and the maximal effect was detected at 48 h. On the other 
hand, the mRNA levels of cytochrome P450 (P450scc), which is a rate-limiting enzyme in 
progesterone synthesis, slightly decreased at 24 and 48 h by activin. The maximal effects of activin 
A were detected in concentration range of 25-100 ng/ml. hCG (30 ng/ml) treated granulosa cells 
were used as a positive control for the α-subunit and P450scc mRNA expression. 
 
To study the effect of FS on the basal and activin A-stimulated βB-subunit mRNA levels, increasing 
amounts of follistatin (up to 350 ng/ml) were pre-incubated with or without activin (25 ng/ml). 
Follistatin inhibited the effect of activin A on βB-subunit mRNA levels in concentration-dependent 
manner, but has no effect by itself. Inhibin A had no effect on βB-subunit mRNA levels at any 
concentration or time point tested in the presence or absence of activin A. 
 
Inhibin α-subunit and p450scc mRNA levels were significantly induced when the granulosa cells 
were stimulated with hCG for 24-48 h. The βB-subunit transcript levels were not affected. 
However, co-stimulation of granulosa cells with hCG and activin A prevented the stimulatory 
effect of activin A on βB-subunit mRNA levels. Interestingly, activin A slightly decreased hCG-
stimulated inhibin α-subunit transcript levels. Activin A did not affect hCG-induced βA-subunit 
mRNA levels (data not shown). 
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The expression of activin receptor mRNAs was studied by Northern blot analysis of RNA extracted 
from freshly isolated human preovulatory granulosa cells as well as human GL cells cultured for 5 
or 6 days. The Northern blots were hybridized with single or double stranded DNA probes for 
human ActR-I, ActR-IB, ActR-II and ActR-IIB. Specific transcripts of the expected sizes were 
detected for all four receptor subtypes in both the freshly isolated preovulatory granulosa cells and 
cultured GL cells. The expression of the specific transcripts of inhibin and activin subunit mRNAs 
in preovulatory granulosa cells was also shown. 
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Discussion 
 
1. Cloning and characterization of human type II activin receptors (I) 
 
The open reading frame of hActR-II and hActR-IIB cDNA sequences was constructed from several 
partial overlapping cDNA clones amplified from K562 cells, and human fetal kidney and brain 
RNA, respectively. Human ActR-II cDNA encodes a protein of 513 aa and was 99% identical at 
the amino acid level with the mouse ActR-II (94). In hActR-II we observed one nucleotide 
difference in sequence comparisons to hActR-II cDNAs published by others (126, 127). However, 
the difference did not alter the deduced amino acid sequence. Like the type II activin receptor (94, 
126, 127, 215, 216) the amino acid sequence of hActR-IIB shows more than 98% homology with 
its rodent counterparts (99, 211). The human ActR-IIB cDNA encodes a 512 aa transmembrane 
protein with an extracellular ligand binding domain and an intracellular signalling domain with 
ser/thr specificity. The human sequence differs only by five amino acids from the corresponding 
mouse sequence (99). Three substitutions in the signal peptide, one in the ligand binding domain, 
and one in the C-terminal region was found. 
 
Because four different type IIB activin receptor transcript isoforms are generated in mouse by 
alternative splicing events (99), we examined whether this feature is also characteristic of the 
human ActR-IIB gene. However, based on our RT-PCR studies we did not find any other receptor 
transcript isoforms than the ActR-IIB2 variant in K562 cell and human fetal brain samples. Under 
similar experimental conditions we detected all four splicing variants in mouse NIH-3T3 fibroblast 
RNA, corresponding to earlier results reported by Attisano et al. (99). Peng et al. have confirmed 
our observation by showing that ActR-IIB2 is the only variant of the ActR-IIB in human brain, 
placenta and granulosa-luteal cells (217). However, in human teratocarcinoma cells two isoforms, 
ActR-IIB1 and ActR-IIB2, have been characterized later (129). The ActR-IIB2 variant appears to be 
the most prevalent isoform in the mouse and ActR-IIB sequences reported in other species 
resemble ActR-IIB2 in structure (211, 218-220). The biological relevance of different isoforms is 
still unclear, but the ActR-IIB1 and ActR-IIB2 isoforms appear to bind activin with higher affinity 
than the ActR-IIB3 and ActR-IIB4 variants, which have binding abilities comparable to that of 
ActR-II receptor (99). This suggests that cells bearing ActR-IIB1 and ActR-IIB2 isoforms may bo 
more sensitive to activin than those harbouring type IIB3, IIB4, or II receptors. Different ActR-IIB 
isoforms may also have different binding properties on the other TGF-β family ligands that use 
ActR-IIB in their signal transduction. 
 
Our study suggests that human ActR-IIB RNA is processed to encode the high affinity ActR-IIB2 
receptor. Although we did not characterize the binding properties of ActR-IIB2 Zhou et al. have 
used our cDNA clone in studies determining the signalling properties of ActR-IB isoforms (221). 
Activin A-induced phosphorylation of ActR-IIB complexed with ActR-IB was significantly 
increased compared with that seen with basal phosphorylation. In another study, soluble ActR-IIB2 
protein produced by us has been used to block molar tooth development in mandibular explants in 
mouse (222). 
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2. The tissue distribution of inhibin α, activin βA- and βB-subunit, activin type I and II 
receptor and follistatin mRNAs in human fetal tissues (I, II) 
 
Our studies were originally the first reports to describe the expression of activin α- and β-subunits, 
activin receptor and follistatin transcripts during human development. The highest expression levels 
of the activin signalling components were detected in developing neural and muscular tissues. 
Activin subunit transcripts are differentially expressed and the mRNA levels varied in various brain 
regions. The strongest hybridization signals of βA- and βB subunits were observed in developing 
neural tissues in the cerebrum and spinal cord, whereas no expression of β-subunits was detected in 
the cerebellum. Interestingly, of the neural tissues studied, follistatin was expressed only in the 
cerebellum. Prior to this study the β-subunit transcripts had been localised in developing rat (223) 
and Xenopus (224) central nervous systems, and later a more detailed expression pattern in 
developing rat brain was reported by Andreasson et al. (225). In several models of acute brain 
injury up-regulation of βA-subunit transcript as well as activin A protein has been observed, 
suggesting an important role for activin in neuroprotection (226). 
 
Further confirming the role of activin during the development of the nervous system, we found that 
ActR-IIB and ActR-II mRNAs were abundantly expressed in developing human neural tissues such 
as brain and spinal cord. Subsequently, it has been shown that all four types of activin receptor 
mRNAs are expressed in embryonic rat brain (227), and throughout the adult rat brain the 
expression of ActR-II mRNA is stronger than that of ActR-IIB (172). Studies on non-mammalian 
vertebrates have shown the expression of ActR-II in chicken embryo neural tissues (128) and ActR-
IIB in Xenopus tissue undergoing neurulation (218). Activin promotes neural cell survival in vitro 
(228), stimulates proliferation and inhibits terminal differentiation of several neural cells in culture 
conditions (229). However, homozygous mice carrying null mutations of activin A and/or activin B 
or ActR-II genes do not show any obvious defects in neural development (57-59, 62). This 
discrepancy in the effects of activin in neural tissues may be explained by other TGF-β ligands 
signalling through ActR-IIB, and some compensation by maternal activins in the embryo. 
 
In the developing human muscle, including heart, skeletal muscle and smooth muscle cells of the 
stomach, activin βA-subunit and follistatin transcripts as well as both type II activin receptor 
transcripts were relatively abundantly expressed. The strongest hybridization signal of the 
follistatin was detected in the skeletal muscle. The expression of follistatin is also detected in 
developing muscle of chicken limb (230). Recent data confirms the role of follistatin and type II 
activin receptors in regulating muscle growth. Myostatin, which negatively regulates skeletal 
muscle mass, is suggested to use ActR-IIs in signalling, and its activity can be blocked by follistatin 
(231). Further, the expression of follistatin or the dominant-negative form of ActR-IIB under the 
myosin light-chain promoter/enhancer increases muscle mass similar to that seen in myostatin 
deficient mice (232). 
 
The βA-subunit mRNA expression was strongest in heart. In line with our findings the expression 
of the βA-subunit has been detected in the developing rat (223) and mouse heart (233). However, no 
βΒ-subunit transcripts were detected in the developing murine heart at the same stage (234). The 
expression of ActR-II has been shown in the developing mouse (235) and chicken heart, and in 
myotomes of developing chicken embryos (128). Recently, it was reported that disruption of the 
ActR-IIB gene results in lateral asymmetry of heart and lungs in developing mice (132) suggesting 
that this gene may be mutated in left-right axis abnormalities in humans as well. However, ActR-
IIB mutations were detected only in rare cases of left-right axis malformations (129). 
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The detection of βA-subunit expression in human fetal hematopoietic tissues (bone marrow, spleen, 
liver) is in line with earlier evidence for activin as a hematopoietic regulator (3, 189). In human 
bone marrow cultures and peripherical blood activin is able to increase the proportion of DNA-
synthesizing erythroid progenitors (190). In contrast to human liver, no expression of the βA-
subunit transcript was detected in developing mouse embryos (233). Based on ample evidence of 
the role of activin as a hematopoietic regulator (186, 187, 189, 192-197) it is not surprising that 
several human hematopoietic tissues express activin receptors. In conclusion, the similar 
distribution pattern of activin β-subunits as well as activin type II receptors in the midgestational 
fetus suggests an important role of activin during human development. 
 
The expression of the β-subunits and follistatin was detected in some developing exocrine 
glandular organs. Relatively low but detectable expression levels of ActR-IIB were also found in 
kidney, salivary, pancreas, and adrenal tissues, as well as in fetal hematopoietic tissues including 
spleen, thymus, liver and bone marrow. Mutations of ActR-IIB have been shown to disrupt the 
development of the stomach, pancreas and spleen in mouse (236). In developing rat salivary gland 
the βB-subunit mRNA has been shown to be highly expressed (223), correlating well with our 
findings.  Moreover, by in vitro organ cultures of the developing mouse kidney, salivary gland and 
pancreas rudiments we have observed that the epithelial branching morphogenesis of these tissues 
is severely disturbed by the addition of exogenous activin (36). In transgenic mice expressing the 
truncated ActR-II under the β-actin promoter the attenuated signalling of activin A or related 
ligands is suggested to increase the number of nephrons by enhancing the branching of ureteric 
buds in the developing kidney (237). A role for activin in the development of the kidney is also 
supported by the study showing ActR-II and ActR-IIB transcripts in chicken (128) and mouse (233) 
developing kidney, respectively. The effects of activin A in the branching morphogenesis have 
been recently reviewed in Ball and Risbridger (238). Although the wide tissue distribution of 
activin β-subunits suggests the importance of activin in developing human tissues, gene targeting 
studies have shown that in mice deficient in both activin βA- and βB-subunits the structure and 
function of the organs studied were not affected (57). Thus, it seems that other activin subunits or 
growth factors using the same signalling components are able to substitute for the effects of activin. 
 
3. The expression and regulation of activin βA-subunit during induced differentiation 
of human erythroleukemia K562 cells (IV) 
 
In human erythroleukemia K562 cells, activin regulates both mitogenesis (189, 239) and 
differentiation-related phenomena such as hemoglobin production (189, 199, 239). In addition to 
activin, TGF-β is also able to induce erythroid differentiation of K562 cells (189, 240). However, 
neither of these growth factors affects activin βA-subunit mRNA or protein expression in these 
cells. Instead the expression of the activin βA-subunit mRNA and protein is induced by the phorbol 
ester TPA which activates protein kinase C (241) and megakaryocytic properties in K562 cells 
(205). The 5' untranslated region of the human activin βA-subunit gene includes promoter 
sequences and various potential enhancer sites of which TPA and cAMP-responsive elements are 
functionally necessary for transcriptional regulation of βA-subunit gene in human fibrosarcoma 
HT1080 cells (39). TPA-induced expression of βA-subunit mRNAs was clearly observed in K562 
cells as well. By Northern blotting five different βA-subunit mRNA species (6.4-, 4.3-, 3.0-, 2.8-, 
and 1.8-kb) were detected, with main sizes of 3.0- and 2.8-kb. Consistent with our findings, the 
expression of multiple βA-subunit mRNAs in the size range of 1.7- to 6.0-kb has also been reported 
in other human cell culture models (7, 31, 40, 42, 44, 48, 242). Different transcription start sites 
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(45) or alternative polyadenylation signals (44) may be responsible for the existence of the 
differently sized βA-subunit mRNAs. 
 
TPA induces the expression of activin βA-subunit mRNA in K562 cells both in a time- and 
concentration-dependent manner. The maximal response was seen at 24 h whereafter the mRNA 
levels decreased. However, in other cultured cells TPA-induced βA-subunit mRNA expression 
shows differential kinetics. In human fibrosarcoma HT1080 cells (243) and in murine bone marrow 
stromal cell lines, MC3T3-G2/PA6 and ST2 (197), TPA increases βA-subunit mRNA expression 
rapidly and transiently with maximal levels at 6h and 4h, respectively. By contrast, in human 
granulosa-luteal cells (212) and in human fetal adrenal cells (42) βA-subunit mRNAs are rapidly 
induced within 2-4 h and the levels remain increased up to 48 h. The TPA-induced expression of 
βA-subunit mRNA in K562 cells resembles that seen during TPA treatment of human THP-1 (7) 
and HL-60 cells (242), where βA-subunit transcripts are slowly induced and remain elevated up to 
48 h. Thus, the regulation of βA-subunit mRNAs by TPA seems to differ in distinct cell types 
suggesting tissue specific regulation of the βA-subunit gene. 
 
Using Western and ligand blotting analyses we evaluated whether the TPA-induced changes of βA-
subunit mRNA levels are reflected of the protein level in K562 cells. We observed that K562 cells 
secrete fully processed immunoreactive 25 kD activin A protein in response to TPA stimulation and 
in reducing conditions the protein is seen as the expected 14 kD monomer. Labelled follistatin was 
used in ligand blotting analyses to further confirm that the 25 kD protein exhibits follistatin binding 
capacity. Thus, K562 cells secrete considerable amounts of processed activin A protein. In line 
with our results, it has been reported that TPA-stimulated K562 cells produce erythroid 
differentiation factor bioactivity (244). Thus, the production of immunologically and biologically 
active activin A protein is clearly characteristic for K562 cells induced toward the megakaryocytic 
differentiation lineage by TPA. 
 
We also determined the role of the cAMP-activated signalling pathways in the regulation of activin 
βA-subunit mRNA levels in K562 cells. Prior to this study cyclic AMP had been shown to induce 
activin βA-subunit mRNAs at least in human placental cells (245), granulosa-luteal cells (212), 
adrenal cells (42) and in HT1080 cells (39, 243). However, in K562 cells no induction of βA-
subunit transcript by cAMP-analogue, 8-Br-cAMP, was observed. Thus it seems that the regulatory 
mechanisms controlling the mRNA levels of the βA-subunit differ between cell lineages. 
Interestingly, co-treatment of K562 cells with both 8-Br-cAMP and TPA significantly increased the 
expression of activin βA-subunit mRNA levels compared with mRNA levels induced by TPA 
alone. The synergistic induction of the activin gene expression by cAMP and TPA has been 
reported also in human fibrosarcoma HT1080 cells (243). 
 
4. The expression and regulation of activin receptors in human K562 erythroleukemia 
cells (I, IV) 
 
 
We have demonstrated that all four known activin receptor mRNAs are expressed in human K562 
erythroleukemia cells, which fits well with the finding that kinase activities of both type II and type 
I receptors are required for activin signalling (200). Kinase-deficient ActR-II abrogates activin-
induced erythroid differentiation (246) and the dominant-negative mutant of ActR-IB inhibits 
transcriptional activation and growth suppression induced by activin in K562 cells (221). 
Furthermore, increasing the levels of ActR-IB and ActR-II using an inducible promoter enhanced 
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the effects of activin on erythroid differentiation in K562 cells, demonstrating that both ActR-IB 
and ActR-II are physiologically important receptors for activin (201). Consistent with this 
observation, ActR-II in concert with activated mutants of either ActR-I or ActR-IB induces 
hemoglobin expression in another erythroleukemia cell line, mouse F5-5 cells (247). On the other 
hand, only ActR-IB and ActR-II were detected by RT-PCR in mouse F5-5.fl cell line, in which 
erythrodifferentiation is induced by activin (248). 
 
By Northern analysis we detected the specific 4.0- and 5.2-kb transcripts for ActR-I and ActR-IB, 
respectively. Results from primer extension studies suggest that tissue specific alternative 
transcription start sites might be used for expression of the mouse ActR-I gene, resulting in variable 
sizes of the 5' untranslated region (148). Two major transcripts, 3.0- and 6.0-kb and 2.5- and 10-kb, 
were observed for both ActR-II and ActR-IIB, respectively. A very weak signal of 2.1-kb was also 
detected with the ActR-IIB probe. If ActR-II transcripts are structural counterparts of the respective 
mouse mRNAs they are likely to arise from the use of different polyadenylation signals during the 
transcription of the ActR-II gene. In the mouse ActR-II gene a transcription start site together with 
a polyadenylation signal gives rise to the 3.0-kb transcript (123). When mActR-II was originally 
cloned, a cDNA clone expanding beyond the 3.0-kb transcript polyadenylation signal was reported, 
suggesting that a longer transcript also arises during mActR-II transcription, and supporting our 
finding of the existence of a 6.0-kb mRNA for the human receptor (94). The relative expression 
level of these two transcripts is regulated in a tissue- and developmental-stage-manner in 
mammalian tissues (169, 249, 250). Although the genomic organization of hActR-IIB has been 
reported (130), there are still not sufficient data available on the 3' and 5' untranslated regions of the 
ActR-IIB gene from any species to predict the nature of these different transcripts. However, 
different transcript sizes have been detected by Northern analysis at least in P19 mouse embryonic 
carcinoma cells (2.4-, 3.8-, 11- and 14-kb) (233) and bovine tissues (2.0-, 2.3- and 10-kb) (131), the 
latter correlating well with the length of human ActR-IIB mRNA species. 
 
The expression levels of type I and IB transcripts are relatively low in untreated K562 cells but they 
are up-regulated during megakaryocytic differentiation of these cells by TPA in a time-dependent 
manner. By contrast, TPA did not affect the steady-state levels of hActR-II and IIB mRNAs. 
Similarly, TPA in human HL-60 promyelolytic leukemia cells does not regulate the expression of 
ActR-IIB either. Although we did not observe regulation of ActR-II or ActR-IIB mRNAs in K562 
or HL-60 cells, these mRNAs are regulated in other systems in a tissue- or cell-specific manner 
(251-253). In K562 cells, the ActR-IIB mRNAs are somewhat more abundantly expressed than 
ActR-II transcripts and induction of K562 cells by TPA does not affect their relative expression 
levels. Although the expression of type I receptor mRNAs were stimulated by TPA treatment, 
neither type I receptor nor type II transcripts were affected during activin-induced erythroid 
differentiation. The co-ordinated up-regulation of activin βA-subunit and its type I receptors by 
TPA suggests that activin might play a role in megakaryopoiesis. According to present knowledge 
the overall role of activin in blood formation is considered to be secondary, not primary. Thus, 
activin fine-tunes rather that drives the differentiation of hematopoietic progenitor cells. 
 
5. The regulation of activin βB-subunit mRNA in cultured human granulosa-luteal cells 
(III) 
 
The data regarding the expression and regulation of activin and inhibin subunits and follistatin 
suggest that these proteins are likely to have important roles in folliculogenesis, oocyte maturation 
and the function of corpus luteum [reviewed in Knight and Glister (176)]. In our studies, we have 
used human granulosa-luteal (GL) cells as an activin responsive cell model. These cells are 
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obtained from women undergoing infertility treatment for in vitro fertilization program. GL cells 
can be maintained in primary cultures and they provide a model for studying hormonal regulation 
of late follicular to early luteal granulosa cells. We have observed that human granulosa-luteal cells 
express inhibin α-subunit and activin βA- and βB-subunit genes (204). Confirming our findings, 
activin A and inhibin A proteins are produced by human GL-cells (181, 254). To further analyse 
their biological role in ovarian physiology, we studied whether activin or inhibin are able to 
regulate their subunit or receptor mRNA levels. The clear induction of activin βB-subunit mRNA 
levels was observed by activin A in concentration- and time-dependent manner without affecting 
basal α- and βA-subunit mRNAs in human GL cells. Recently this finding has been confirmed by 
Liu et al. (255). In addition, activin A increases inhibin B secretion in human GL-cells (256). We 
have observed in this study that follistatin prevents the stimulatory effect of activin A on βB-subunit 
mRNA levels further confirming the specificity of the stimulatory effect of activin A. In addition to 
activin A, TGF-β and BMP-2 are also able to induce the expression of activin βB-subunit 
expression in human GL cells (257, 258). We have detected that the ser/thr kinase receptors and 
Smad signalling proteins needed for activin A, TGF-β and BMP-2 signalling are expressed in 
human GL cells. Recent studies confirm that BMP-2 and activin A activate the Smad1 and Smad2 
pathways, respectively, as well as inhibin B production in human GL cells (259). The expression of 
inhibin, activin and activin receptors in developing human follicles and GL-cells is presented in 
figure 6. 
 
Our results on the regulatory effects of activin A on inhibin and activin subunit mRNA levels differ 
markedly from those reported in rat granulosa cells. Activin-induced expression of both the α- and 
βA-subunit mRNAs has been shown previously in rats, but no data on βB-subunit mRNA levels 
have been presented (182). However, activin A-induced production of both inhibin A and B has 
been recently reported in cultured rat granulosa cells (260). Several reports have indicated that the 
distribution of inhibin/activin subunits in the primate ovary is different from that in ovaries of non-
primate mammals (261). In human and other higher primate ovaries α- and βB-subunits are the 
major mRNA species expressed in small antral follicles, whereas α- and βA-subunits are expressed 
by dominant follicles (177, 261, 262). By contrast, the expression of α-subunit mRNA gradually 
increases from the early primordial follicle to the preovulatory follicle in rat, and the βA- and βB-
subunit mRNA levels are induced in antral follicles concomitant with the LH and FSH surge (182, 
263). However, in the rat corpus luteum levels of the three subunits have been low, or undetectable 
(182). In human corpus luteum, strong inhibin α and moderate activin βA-subunit mRNA signal has 
been detected, but no βB-subunit mRNA was observed (177). 
 
Although hCG induces α- and βA-subunit mRNA levels in human GL-cells (264) we were unable 
to detect any induction of basal βB-subunit mRNA levels by hCG (Fig. 6). In agreement with our 
studies, it has been shown at the protein level that hCG and recombinant human LH, which uses the 
same receptor as hCG, induce inhibin A and activin A secretion but not inhibin B production (254, 
265). Interestingly, recombinant human LH even down-regulates the expression of the βB-subunit 
mRNA (255). 
 
Our studies on the effect of gonadotropins on inhibin/activin subunit levels indicate that the three 
subunits are regulated through distinct mechanisms in human GL cells (Fig. 6). The α-subunit is 
induced by gonadotropins by relatively slow kinetics (264), while activin A decreases hCG-induced 
α-subunit mRNA levels. The βA-subunit mRNA is rapidly and transiently induced by 
gonadotropins (264), but activin A does not influence its levels. The expression of βB-subunit 
mRNA is not induced by hCG, but hCG prevents the stimulatory effect of activin A. Subsequently, 
it has been shown that the second messenger of hCG, cAMP, has no stimulatory effect on secreted 
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inhibin B levels in human GL-cells (256). This data fits well with our data on βB-subunit mRNA 
expression. The inability of hCG or cAMP to induce βB-subunit mRNA levels in human GL cells 
was somewhat surprising, as the human βB-subunit gene promoter region is known to contain 
several cAMP-responsive elements (47). Further, βB-subunit mRNA levels are induced by cAMP in 
human fetal testicular cell cultures (48) and placental cells (245). Although no cAMP-responsive 
elements have been identified in the rat βB-subunit gene promoter, the expression of both βB-
subunit transcripts is increased by cAMP (49, 266). Hence the putative AP-2 binding sites, able to 
mediate transcriptional induction by the protein kinase-A pathway (267), may mediate the effects 
of cAMP on βB-subunit gene transcription. The activity and regulation of the βB-subunit promoter 
has been examined by CAT assay, revealing that in mouse Leydig tumour cells neither of the two 
βB-subunit promoter regions is responsive to cAMP (268) although cAMP induced βB-subunit 
promoter activity has been observed in the mouse Sertoli cell line (269). This indicates that cAMP 
may regulate the activity of the βB-subunit promoter in a cell-specific manner in the mouse. The 
regulation of βB-subunit promoter activity has not been studied in humans.  
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6. The expression of activin receptor mRNAs in human granulosa-luteal cells (III) 
 
We have shown that freshly isolated human granulosa-luteal cells as well as cultured GL cells 
express the specific transcripts of all four activin receptors, results confirmed later by others (Fig. 
6) (217, 270). There is a strong correlation between the transcriptional activity of ActR-I and ActR-
II, and ActR-IB and ActR-IIB in human granulosa cells, suggesting that these receptors might be 
functionally linked in activin signal transduction (271). The transcript sizes of activin type I 
receptors in human GL cells correspond to those observed in human erythroleukemia K562 cells 
and other human tissues (92, 97). The major transcripts for ActR-II and ActR-IIB were 3.0- and 
2.5-kb, respectively, whereas the 6.0- and 10-kb transcripts were hardly detectable. Interestingly, in 
bovine reproductive tissues (ovary, corpus luteum, uterus) (250) and in rat ovaries (169) the major 
band for the type II activin receptor was 6-kb. The expression of mRNAs for all four activin 
receptors has subsequently been detected in human, mouse and rat oocytes (184, 272). In mice 
deficient of ActR-II follicles arrest at an early antral stage, consistent with the key role for activin 
in GC proliferation and differentiation (273). Recently, Pangas et al. (185) have reported the co-
localization of the proteins involved in the activin signal transduction cascade in human follicles. 
The expression of ActR-IIB is mainly restricted to granulosa cells of the small antral follicles, 
whereas ActR-II is intensively expressed also in atretic follicles. Co-localization of activin 
signalling components is limited to a few developmental stages including granulosa cells of early 
atretic follicles. However, dominant follicles and corpus luteum, which best corresponds our GL-
cell model, were not included in this study. 
 
7. ActR-IIB interacts with multiple TGF-β superfamily ligands 
Considerable effort has been devoted to identify the receptors for individual TGF-β superfamily 
ligands. Although over 40 ligands have been identified only five type II ser/thr kinase receptor 
genes and seven type I receptor genes are known in vertebrates so far. The diversity of ligands 
suggests that some receptors probably bind multiple ligands and form several type II/type I receptor 
complex combinations in signalling. Among the known type II receptors AMHR-II and TβR-II 
(100) have been shown to be ligand specific with little or no cross-reactivity to other factors. In 
contrast, activin type II receptors have shown to interact with multiple ligands. 
 
ActR-IIB binds not only activin A and B, but also OP-1/BMP-7, BMP-2 and GDF-5 in the presence 
of BMP type I receptors (Fig. 7) (138, 155, 156). Confirming the cross-talk between the activin 
signalling system and BMP receptors, membrane glycoprotein endoglin interaction with BMP-2 
and BMP-7 is detected in the presence of ActR-IIB but not when BMPR-II forms the signalling 
complex (88). Mesoderm formation induced by activin, Vg1, BMP-4 or Xenopus nodal-related 
proteins (Xnrs) can be blocked by truncated dominant-negative ActR-IIB in developing Xenopus 
embryos (5, 274). BMP-4 induces distinct cellular responses in Xenopus embryogenesis depending 
on the receptor combination that it uses for signalling (275). Recently, it has been detected that 
ActR-IIB can act as type II receptor for Nodal and Xnr1 together with ActR-IB and ALK-7 (Fig. 7) 
(153). Mice lacking ActR-IIB have defects in left-right axis formation, which is characteristic of 
Nodal activity as well (132, 133). In addition, the ActR-IB mediated pathway activates Smad-2, 
which has been shown to affect left-right patterning in mesoderm-formation (276, 277). 
Myostatin/GDF-8 binding to ActR-IIB has been detected both in vitro and in vivo using transgenic 
mice with dominant-negative ActR-IIB (231). Truncated ActR-IIB increases muscle mass in these 
mice resembling the phenotype of myostatin deficient mice. Myostatin binding can be inhibited by 
follistatin, and it has been proposed that myostatin presumably activates the same signalling 
pathway as activin although the type I receptor involved is yet to be defined. Gene targeting studies 
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have shown that none of the phenotypes observed in ActR-IIB deficient mice were related to the 
defects seen in mice deficient in activin βA- and βB-subunits (57, 132) confirming the hypothesis 
that ActR-IIB probably transduces the signals of multiple TGF-β family ligands during normal 
development. 
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Figure 7. Schematic illustration of the signalling mechanism of TGF-β family members via 
ActR-IIB. In addition to activin, several other TGF-β family members use ActR-IIB in their signal 
transduction. Ligand-induced complex formation between specific type I receptor (ALK2-7) and 
ActR-IIB determines which intracellular downstream components, Smads, are activated by 
phosphorylation. In the nucleus activated Smad complexes together with other transcription factors 
regulate target gene responses. 
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Summary and concluding remarks 
 
During the last decade the expression of activin β-subunits has been extensively studied in order to 
understand the roles of activins as autocrine/paracrine regulators of cell functions. To elucidate the 
possible physiological functions of activins it is crucial to detect where activin signalling 
components are expressed and how they are regulated. We investigated the expression and 
regulation of activin subunits and its receptors in developing human tissues as well as in different 
activin responsive cell cultures. Human erythroleukemia K562 cell line contains a functional 
activin signalling pathway and is commonly used as a model system for erythroid differentiation 
and activin signalling. In addition to facilitating studies for erythroid differentiation, the K562 cells 
offer a tool to approach early steps of megakaryoblast commitment and differentiation. In the ovary 
activins are local growth factors which regulate folliculogenesis. Human granulosa luteal cells used 
in this study were obtained from women undergoing hormone treatment for in vitro fertilization. 
These cells are well on the pathway to luteinization and thus represent cells forming corpus luteum 
rather than granulosa cells from growing follicles. However, this model has turned out to be a 
suitable model for studying the regulation of activin and inhibin subunits in vitro. 
 
In the first study we characterized the primary structure of human ActR-II and ActR-IIB. 
According to cDNA sequences, human ActR-II and ActR-IIB appear to be transmembrane ser/thr 
kinase receptors corresponding to mouse sequences. Human ActR-IIB represents an ActR-IIB2 
alternatively spliced variant. Like TGF-β superfamily ligands, type II activin receptors are highly 
conserved between mammalian species. 
  
We demonstrated the tissue distribution pattern of activin and inhibin subunits, follistatin and type 
II activin receptors in developing human tissues. Strong co-expression of type II activin receptor 
and activin β-subunit mRNAs were detected in developing human neural and muscular tissues. In 
glandular tissues both activin β-subunit and ActR-IIB mRNA expression levels were low but 
detectable. In bone marrow only activin βA-subunit and ActR-IIB were observed. Follistatin was 
not detected in any of the hematopoietic tissues. According to our findings inhibin appears to be 
restricted to the adrenals and testes. Taken together, all activin receptors studied here show wide 
distribution pattern, and they seem to be controlled in tissue- and gene-specific manner during 
human development. 
 
We investigated the regulation of activin A and its type I and II receptors in K562 cells. During 
megakaryocytic differentiation the expression of both of the type I activin receptors were co-
ordinately upregulated with the expression of the activin in K562 cells by TPA. 8-Br-cAMP 
enhanced the inducing effect of TPA on expression of activin βA-subunit mRNA. In contrast, 
neither activin nor TGF-β1 induced βA-subunit, ActR-I or ActR-IB expression during erythroid 
differentiation. The expression levels of activin type II receptor transcripts were not regulated 
during K562 cell differentiation. Our data suggest that activin may play a role in megakaryopoiesis, 
and that type I and II activin receptors are differentially regulated in K562 cells. 
 
Cultured human GL-cells express all three activin/inhibin subunit mRNAs. We studied the effect of 
activin A on the expression of activin βA- and βB-subunit as well as inhibin α-subunit mRNA levels 
in human GL-cells. Activin A induced the low basal levels of activin βB-subunit transcripts without 
affecting βA- or α-subunit mRNA levels. Although hCG has been shown to induce activin βA-
subunit and inhibin α-subunit transcript levels it did not affect the βB-subunit transcripts. By 
contrast, hCG suppressed the effects of activin A on βB-subunit mRNA expression. Thus regulation 
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of the βB-subunit clearly differs from that of βA- and α-subunits in human GL-cells. The expression 
of all currently known activin receptor mRNAs was detected in cultured GL-cells as well as 
preovulatory granulosa cells, confirming that activin A may act as an inducer of βB-subunit mRNA 
levels in these cells. 
 
Taken together, our data suggests that the expression of activins and its receptors are differentially 
regulated in distinct human tissues and cell models. The multifunctional nature of activin requires 
tight control. The expression profiles of activin receptors and Smads in the target cell suggest 
which particular cellular responses are induced by activins or other ligands using activin receptors. 
Studies on transgenic mice models suggest that activins are perhaps developmentally less important 
than previously anticipated. In contrast, mice lacking activin signalling pathway genes have severe 
defects that cannot be rescued by other factors. The Smad pathway seems to be the core of the 
activin signalling mechanism, but the transcriptional response to activins also depends on what 
other signals are being received by the cell. In addition, transcription factors present in the cell 
determine the response to Smad interaction. Thus, the final response depends as much on the 
activity of receptors, Smads and co-modulators that control and determine targets as it does on the 
activin signal itself. 
 
Recent studies support the hypothesis that the inappropriate activation or inactivation of the activin 
receptor mediated signalling pathways could contribute to human diseases. Mutations in the ActR-
IIB gene have been associated with left-right axis malformation in humans (129). Additionally, 
mutated ActR-IB has been detected in pancreatic cancer (278). Smads may inhibit cell division, 
and, consequently, mutations in Smad proteins have been reported to be involved in several cancers 
(279). New technologies hold a promise for better understanding of the contribution of activin 
signalling components to various disease conditions. One important task for the future is to identify 
those genes that respond to TGF-β superfamily signals. If activin receptors, Smads or co-regulators 
could be organ-specifically targeted in humans, that could provide new therapeutic possibilities 
within biomedical science. 
 
As the human genome has been sequenced, it is important to obtain a general view on how the over 
40 TGF-β receptor family ligands signal through the currently known 12 receptors and what 
relevant co-receptors are needed. Several growth factors are known to bind to the same type II 
ser/thr kinase receptor, which enables signalling by multiple growth factors via a limited set of 
available receptor types. How many more genes of TGF-β family ligands or receptors will still be 
found and what is the impact of heterodimerization of ligand monomers remains to be resolved. 
The newly developed functional genomics and the ability to monitor gene expression at the RNA 
and protein levels in detail provide an important approach for the future. 
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